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Cyclic-39,59-nucleotide phosphodiesterase isozymes in cell biology and through intracellular mediation of a specific adenine nu-
pathophysiology of the kidney. Investigations of recent years revealed cleotide, cyclic-39,59-adenosine monophosphate (cAMP),
that isozymes of cyclic-39,59-nucleotide phosphodiesterase (PDE) are
and the era of second messengers and intracellular sig-a critically important component of the cyclic-39,59-adenosine mono-
phosphate (cAMP) protein kinase A (PKA) signaling pathway. The naling was born. Shortly after the discovery of cAMP, an
superfamily of cyclic-39,59-phosphodiesterase (PDE) isozymes consists analogous guanine nucleotide, cyclic-39,59-GMP (cGMP),of at least nine gene families (types): PDE1 to PDE9. Some PDE
was identified [2], and this nucleotide turned out to playfamilies are very diverse and consist of several subtypes and numerous
PDE isoform-splice variants. PDE isozymes differ in molecular struc- a similar—albeit not identical—role in cellular signaling
ture, catalytic properties, intracellular regulation and location, and as cAMP [3]. Since then, a number of other second mes-sensitivity to selective inhibitors, as well as differential expression in
sengers and related components of intracellular signalingvarious cell types. A number of type-specific “second-generation” PDE
inhibitors have been developed. Current evidence indicates that PDE pathways have been discovered. However, the intricate
isozymes play a role in several pathobiologic processes in kidney cells. mechanisms by which cAMP and cGMP, the archetypalIn rat mesangial cells, PDE3 and PDE4 compartmentalize cAMP sig-
second messengers, act in cellular signaling are far fromnaling to the PDE3-linked cAMP-PKA pathway that modulates mito-
genesis and PDE4-linked cAMP-PKA pathway that modulates genera- clarified, and novel, often surprising, aspects of cyclic
tion of reactive oxygen species. Administration of selective PDE nucleotide signaling functions are still being revealed.isozyme inhibitors in vivo suppresses proteinuria and pathologic
The cellular content and, by extension, biological ef-changes in experimental anti-Thy-1.1 mesangial proliferative glomeru-
lonephritis in rats. Increased activity of PDE5 (and perhaps also PDE9) fects of cAMP or cGMP are, in principle, defined by
in glomeruli and in cells of collecting ducts in sodium-retaining states,
the balance between activities of synthesizing enzymesuch as nephrotic syndrome, accounts for renal resistance to atriopep-
tin; diminished ability to excrete sodium can be corrected by adminis- cyclases, adenylate cyclase and guanylate cyclase, respec-
tration of the selective PDE5 inhibitor zaprinast. Anomalously high tively, and catabolizing enzymes, the cyclic 39,59-nucleo-
PDE4 activity in collecting ducts is a basis of unresponsiveness to
tide phosphodiesterases (PDE; EC 3.1.4.17) that hy-vasopressin in mice with hereditary nephrogenic diabetes insipidus.
Apparently, PDE isozymes apparently also play an important role in drolyze the 39-phosphoester bond of cAMP and cGMP
the pathogenesis of acute renal failure of different origins. Administra- to their respective biologically inactive noncyclic nucleo-
tion of PDE isozyme–selective inhibitors suppresses some components
tides 59-AMP and 59-GMP (Fig. 1).of immune responses to allograft transplant and improves preservation
and survival of transplanted organ. PDE isozymes are a target for The question of how cAMP is synthesized by cyclases
action of numerous novel selective PDE inhibitors, which are key and how this biosynthesis is regulated by hormonal
components in the design of novel “signal transduction” pharmacother-
agents attracted immediate and enduring attention andapies of kidney diseases.
has been extensively studied by many investigators. On
the other hand, although the existence of cyclic nucleo-
tide PDE activities was discovered soon after the discov-More than 35 years ago, Robison, Butcher and Suther-
ery of cyclic nucleotides [4], these enzymes did not attractland [1] discovered that hormones, autocoids, and neuro-
as much attention. Perhaps cAMP- and cGMP-hydrolyz-transmitters exert their regulatory effect on cell functions
ing enzymes have been tacitly perceived as commonplace
hydrolases with rather static function, that is, inactivation
Key words: cAMP, extracellular signaling, collecting ducts, protein of cAMP or cGMP in the cell when hormonal effects
kinase A, mesangial proliferative nephritis, nephrogenic diabetes insip-
are terminated and these second-messenger nucleotidesidus, PDE superfamily.
are no longer needed. The hydrolytic products 59-AMP
Received for publication February 6, 1998 and 59-GMP are then duly recycled into the general pooland in revised form April 8, 1998
of purine nucleotides.Accepted for publication April 9, 1998
Updated August 19, 1998 It has long been known, but little appreciated, that in
most cells and tissues the maximal catalytic capacity for 1999 by the International Society of Nephrology
29
Dousa: Cyclic-39,59-nucleotide PDE isozymes30
Fig. 1. General scheme of cyclic 39,59-nucleo-
tide metabolism. Abbreviations are: AdC, ad-
enylate cyclase; GC, guanylate cyclase; PDE1-
PDE9, types (gene families) of PDE isozymes.
PDE3, PDE4, and PDE7 and PDE8 hydrolyze
only cAMP (cAMP-PDE). PDE5, PDE6 and
PDE9 hydrolyze only cGMP (cGMP-PDE),
and isozymes PDE1 and PDE2 accept both
nucleotides as a substrate. The thickness of
the lines reflects the catalytic capacity of the
pathway.
cAMP and cGMP synthesis is considerably (,10 times) pharmacologic agents suited for “signaling transduction
pharmacotherapy” [21].less than the capacity for hydrolysis by PDEs (Fig. 1)
and is one of the key factors determining turnover of In several areas of medicine—namely, in pathophysi-
ology and pharmacology of the cardiovascular, thoracic/cAMP [5, 6]. This feature is consonant with general ob-
servations that even partial inhibition of PDE results in pulmonary, and endocrine systems, in the pathobiology
a many-fold increase in the accumulation of cAMP and of immune-inflammatory processes, and in neurosci-
the activation of the cAMP-activated protein kinase, or ence—a keen interest has developed in the study of PDE
protein kinase A (PKA), signaling pathway [7–9]. It fol- isozymes, and considerable knowledge of the PDE sys-
lows that PDEs in intact cells must operate at lower tem has recently accrued in these fields. On the other
than maximal capacity and that they should be tightly hand, recent progress in the field of PDE isozyme re-
regulated [5, 10–12]. Furthermore, it is increasingly evi- search did not attract much interest of investigators in
dent that PDE activities in cellulo serve more than one nephrology and renal physiology. Consequently, our cur-
function. In addition to determining the amplitude of rent knowledge of the role of PDE isozymes in biology
cyclic nucleotide–mediated hormonal responses, PDE and pathobiology of renal cells and kidney is relatively
also modulates the duration of the signal, and in some limited. This review provides a concise overview of the
systems they also modulate rapid oscillation of cyclic basic biology and pharmacology of PDE isozymes in
nucleotides, as exemplified in regulation of PDE’s func- general, and then reviews the current knowledge and
tion [8, 10]. Current evidence shows that activities of concepts pertaining to the role of PDE isozymes in biol-
PDE are regulated by multiple inputs from other signal- ogy and pathophysiology of the kidney.
ing systems and are a crucial point of “cross-talk” be-
tween signaling pathways [8] and an important point of
SUPERFAMILY OF PHOSPHODIESTERASE
integration of intracellular regulatory networks [10–12].
ISOZYMES IN VERTEBRATES
Moreover, PDEs may be key factors in cellular compart-
Taxonomy of phosphodiesterasesmentalization of cyclic nucleotides [8, 13–16].
In spite of the initially low profile of PDEs, a small, For many years, PDEs were identified and known
almost solely by their catalytic and regulatory propertiesdetermined cadre of investigators persisted in the study
of PDEs as a primary subject of investigation. This effort [22]. For example, there were recognized PDEs with
high Km and low Km for the substrate, PDEs dependenthas yielded, mainly in recent years, a veritable explosion
of new and fundamental information on PDEs and has for their activity on calcium (Ca21) and calmodulin
(CaM), or PDEs stimulated by cGMP, etc. [10–12, 22].established the novel concept of PDEs as intricate, inter-
related, and highly relevant components of cellular sig- Recent advances in molecular genetics and biochemistry
have allowed the cDNA sequences and amino acid struc-naling systems. It is now established that vertebrate
PDEs comprise a large superfamily of related isozymes tures of many currently known PDE isozymes to be
determined. This analysis has revealed that vertebrateand their isoforms [10–12, 17, 18] that are diverse in terms
of structure, localization, regulation, and sensitivity to PDEs constitute a large superfamily of related isozymes,
comprising several gene families (types), single gene prod-selective PDE inhibitors [7, 9, 18–20]. An attractive fea-
ture of PDE isozymes is the fact that PDEs are targets for ucts (subtypes), and numerous isoforms-splice variants
[17, 19, 23], which are schematically shown in Figure 2.a number of synthetic PDE isozyme–selective inhibitors
[7–10]. These compounds are both experimental tools The systematic classification of the PDE isozyme system
[10–12, 19, 23] is based primarily on cDNA genetic codessingularly useful in the study of the role of PDEs in
cyclic nucleotide signaling and represent a novel class of and primary amino acid sequences, which can virtually
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Fig. 2. Schematic depiction of superfamily of
vertebrate PDE isozymes (class 1). The num-
ber of isoforms, currently known, is in paren-
theses.
unequivocally identify any mammalian PDE isozyme [5, cGMP, is not sensitive to 3-isobutyl-1-methyl-xanthine
(IBMX) and other tested PDE inhibitors, and is inhibited9, 10, 17, 19, 23]. When, based on these studies, the exis-
tence of PDE gene families became recognized, the first by Ca/CaM [24]. Otherwise, very little is known about
the properties and biologic significance of the enigmaticfive PDE gene families were designated by Roman nu-
merals as PDE-I through PDE-V [7–9, 18]. In 1994, an cCMP, including cCMP cyclase and cCMP-PDE [24].
Most gene families (types) of vertebrate PDEs areinternational committee of investigators in the PDE field
adopted a modified, updated nomenclature of PDE iso- comprised of more than one isogene; a product of a
single PDE isogene is also called a “PDE subtype” (Fig.zymes [10, 23]. In this classification system, gene families
(types) of the PDE are designated by Arabic numerals 2). Some PDE gene families, namely PDE1 and PDE4,
are very diverse, whereas for others, such as PDE2,[10, 23], for example, PDE4 instead of formerly PDE-
IV [7, 9, 18]. This nomenclature (Fig. 3) is also in confor- PDE5, PDE7, PDE8, or PDE9, the existence of well-
documented isogenes has not yet been reported (Fig. 2).mity with the Gene Bank nomenclature system and iden-
tifies PDE isozymes by vertebrate species, gene family, Furthermore, most PDE gene products have one or more
mRNA splice variants (PDE isoforms) that are the resultsingle gene product, and isoform-splice variant. As cur-
rently known, the superfamily of mammalian PDE iso- or either alternative splicing of mRNA or alternative
transcription initiation sites [10–12]. PDE isoforms,zymes consists of nine gene families (also called “types”)
denoted PDE1 through PDE9 (Fig. 2). Because this des- “splice variants,” confer an additional layer of diversity
and specificity to the PDE superfamily system; PDEignation of gene families (types) by Arabic numerals was
only introduced recently [23], readers can find the use isoforms are often tissue specific and are selectively ex-
pressed in various tissues and cell types [8, 10, 11, 25–27].of Latin numerals even in recent publications.
The PDE activity that hydrolyzes specifically cyclic- A number of recently discovered PDE isoforms are
known solely by the structure of cDNA sequence, deter-39,59-cytidine phosphate (cCMP), that is, the cCMP-
PDE, remains elusive. A protein with cCMP-PDE activ- mined with the use of recombinant DNA technology, and
the enzymatic properties of such PDE isoforms remainity was isolated from rat liver [24]. The enzyme selec-
tively hydrolyzes cCMP as compared with cAMP and to be determined, in particular, by elucidation of their
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Fig. 3. Current nomenclature of PDE iso-
zymes, an example [10]. The nomenclature
follows criteria for naming PDE isozymes ac-
cording to the entries into LOCUS field of
Gene Bank [23]. The first two letters at the
beginning denote the species by the initials of
taxonomic classification, the following three
letters (PDE) plus Arabic numeral designate
gene family (type), the next letter denotes iso-
gene product (subfamily or subtype), last nu-
meral denotes isoform (splice variant), and
the final letter on the right end allows Gene
Bank to assign a unique LOCUS field designa-
tion based on when the entry was submitted
and also to give different LOCUS names to
conflicting or incomplete sequences [8]. In the
current literature, in an abbreviated version,
the first two letters (species) and the last letter
(Gene Bank LOCUS field designation) often
are not specified. The descriptive abbrevia-
tions for the gene families (types), based on
catalytic and regulatory properties, are often
used alternatively and are listed in Table 1.
catalytic and regulatory properties. Currently, more than PDE monomers that are members of one gene PDE
family show 65% or more amino acid sequence identity,30 PDEs have been identified (Table 1). However, the
number of known PDE isozymes does and will undoubt- but less than 40% identity is found among PDE families
[10, 11, 17, 19]. Interestingly, PDE isozymes of the sameedly continue to increase.
PDE gene family (type) appear to be more homologous
Molecular structure of PDE isozymes across the species than between two members of the
same family within one species. For example, rat isozymeA comparison of the nucleotide sequences of the
PDE3A and corresponding human isozyme PDE3AcDNA of PDE isozymes shows that all PDEs—the en-
have a greater homology than rat isozyme PDE3A andzymes that hydrolyze cyclic 39,59-nucleotides—can be
distinguished as two major distinct groups [17]. One large rat isozyme PDE3B [33]. Localization of genes encoding
PDE isozymes in human and animal chromosomes di-group, “Class I,” includes all vertebrate PDEs and some
yeast enzymes and has as a common feature a catalytic verges widely [8, 19]. As an example, PDE4D is located
on chromosome 2 in rat but on chromosome 5 in humanscore of 250 amino acids or more, whereas “Class II”
PDEs lack this structural feature of a “central core” (Fig. [19], and PDE4B is located on chromosome 5 of rat, but
on chromosome 1 in humans. Within the PDE3 family,4). Included in Class II are some PDEs found in yeasts
(S. cerevisiae) or slime molds (Dictyostelium discoideum) human PDE3A is located on chromosome 12, whereas
human PDE3B is located on chromosome 11 [33].[16, 18]; herein, exclusively vertebrate PDEs of Class I
are covered [17]. Typically, the PDE monomer (Fig. 4) consists of three
domains [8, 10–12]. These include a central catalytic core,Phosphodiesterases of Class I are chimeric, multido-
main proteins that are composed of several different a region that is highly conserved in all vertebrate PDEs
(Class I) consisting of approximately 270 amino acidssegment-domains, each of which is associated with a
particular function [10–12, 17, 19]. The PDE domains and positioned close to the COOH terminus. This core
region is much more similar in terms of amino acid iden-are separated by “hinge” regions, points in which these
PDE domains can be experimentally separated by lim- tity within one individual PDE gene family (more than
80%), rather than between two distinct PDE gene fami-ited proteolysis [11, 12, 17]. It is believed that the great
diversity of the PDE isozyme system might have been lies (,25% to 40%). The central catalytic core domain
of PDEs also contains signature consensus sequencesformed by genetic mechanisms that result in fusion of
various gene domains, which are, putatively, of an evolu- and motifs that are common for all vertebrate PDEs [5,
57]. In this domain, a sequence, HD(L,I,V,M,F,Y)H-X-tionary origin [17]. The common pattern of structural
features of PDE isozyme monomers is in Figure 4. H(A,G)X-X-N-X(L,I,V,M,F,Y), and also motif, E,F
(F,W)-X-X-QGD(R,K,L)E, identify uniquely any verte-As a rule, vertebrate PDEs are dimers of linear 50 to
150 kDa proteins. An exception is the PDE6 family, brate PDE [5, 57]. (The sequence is in single-letter amino
acid symbols; X indicates that any amino acid can bea photoreceptor-specific PDE, which is a tetramer and
consists of at least four types of subunits [10, 11, 49]. present in this position. Groups in parentheses note that
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Table 1. Mammalian PDE isozymes gene families, isogenes and isoforms
Isogene products Properties of products of PDE isogenes (subtypes) and isoforms (products of
Gene family (type) (subtypes) Isoformsc alternative transcription, initiation or splicing)
PDE1 3 (.9)a PDE1A PDE1A1 Km cAMP . Km cGMP, m.m. | 50 kDa, major sources: heart; higher affinity
(CaM-PDE)b (Kact) for Ca21/CaM [10, 20]
PDE1A2 Km cAMP . Km cGMP m.m. | 61 kDa; source: brain, kidney; lower affinity
(Lact) for Ca21/CaM binding [10, 20]; Kact decreased by protein kinase A
(PKA) phosphorylation
PDE1B Km cAMP . Km cGMP, m.m. | 63 kDa; source: brain, kidney, lower affinity
(Kact) for Ca21/CaM binding [10, 20]
Kact decreased by phosphorylatioin via Ca/CaM-protein kinase II [10]; can be
induced by PKC-a and PKC-e [28]
PDE1C PDE1C(1-5) Km cAMP > Km cGMP; m.m. | 75 kDa; source: olfactory bulb, testis, brain,
at least 5 splice variants [29]
PDE2 1 (3) PDE2 PDE2A1 m.m. | 80 kDa, cystosolic form; source: adrenal, liver, heart [30]
(cGS-PDE) PDE2A2 m.m. | 105 kDa, membrane-bound form has N-hydrophobic sequence; source:
heart, brain [31]
PDE2A3 similar to PDE2A2; differs at N-terminal sequence [32]
PDE3 3 (.2) PDE3A lower KicGMP than PDE3B; is activated and phosphorylated by PKA [11, 33, 34]
(cGI-PDE) PDE3B higher KicGMP than PDE3A; is activated by phosphorylation by PKA and also by
insulin-stimulated protein kinase (PDE31K); the pathway includes
phosphatidyl inositol-3 kinase (Pi-3K); N-terminal rich in proline [33, 34]
PDE4 4 (.15) PDE4A PDE4A1A membrane-bound isoform, binds through N-terminal 1-25 amino acids [25, 35, 36]
(cAMP-PDE) PDE4A4B when membrane-bound is 10 times more sensitive to inhibition by rolipram [69]
PDE4A5 isoform that can bind via SH3 domains (class 1 sites) src tyrosine kinases or to
fodrin [37, 38]; is activated by growth hormone [224]
PDE4B PDE4B1 “long isoform” [39]
PDE4B2A “short isoform,” de novo synthesis of the enzyme is induced by cAMP [40, 41]
PDE4B2B “short isoform” [39] can be phosphorylated by MAP kinase at Ser487 close to
COOH terminal region [42]
PDE4B3 “long isoform” [39]
PDE4C isoforms are less frequently expressed, and are less sensitive than other PDE4
subtypes to some selective inhibitors (rolipram, CDP-840, Ro-20 174) [43, 44]
PDE4D PDE4D1 “short isoform” m.m. | 72 kDa; de novo synthesis of the enzyme is induced by
cAMP [12, 40, 41, 45]; present only in cytosol [41]
PDE4D2 “short isoform” m.m. | 68 kDa; de novo synthesis of the enzyme is induced by
cAMP [12, 41]; present only in cytosol [46]
PDE4D3 “long isoform” m.m. | 93 kDa; is activated via phosphorylation by PKA at Ser54
[47]; also is activated by binding of phosphatidic acid [48]; in part membrane
bound [46]
PDE4D4 “long isoform,” binds to SH3 domains [38]; in rat membrane bound [46]
PDE4D5 “long isoform”; in part membrane bound [46]
PDE5 2 (2) PDE5 binds noncatalytically cGMP; is phosphorylated and activated by PKA and/or
(cG-BPDE) PKG [10, 11, 56]
PDE6 3 (2) PDE6A heterotetramer (a, b, gg) prenylated at COOH terminal; inhibitory g subunit
(photoreceptor) PDE6B phosphorylated by PKC; located in retinal rods [19, 49]
cG-PDE PDE6G homotetramer (a9, a9, gg); located in retinal cones [19, 49]
PDE7 1 (2) PDE7A PDE7A1 m.m. 57 kDa, soluble, expressed in multiple tissues [50]
(HCP-7-PDE) PDE7A2 m.m. 50 kDa with N-terminal hydrophobic sequence, membrane bound,
expressed in a skeletal muscle and myocardium; insensitive to rolipram,
enoximone, cGMP, EHNA, zaprinast [51, 52]
PDE8 1 PDE8A PDE8A1 m.m. | 83 kDa, cloned from human, cAMP-specific, low Km 5 55 nm, low VMAX 5
150 pmol/min/mg protein; insensitive to IBMX, rolipram, vinpocetine,
zaprinast, enoximone, SKF94120; is inhibited by dipyridamole IC50 . 9mm;
expressed in multiple tissues, highest in gonads and intestine [53]
PDE8A2 m.m. 95 kDa; cloned from mouse, expressed predominately in testis and liver;
kinetics and inhibitor sensitivity similar to PDE8A1 [54]
PDE9 1 (2) PDE9A PDE9A1 m.m. 62 kDa; cloned from mouse, cGMP-specific, low KmcGMP 5 70 nm; insensitive
to: IBMX, EHNA, rolipram, PDE3 inhibitors; inhibited by SCH 518666 Ki .
1.5 mm, zaprinast Ki | 20 nm; expressed predominately in the kidney [55]
PDE9A2 nm | 69 kDa; cloned from human, low KmcGMP 5 170 nm; VMAX 5 4.9 nmol/min/
mg protein; insensitive to: IBMX, dipryidamole, rolipram, vinpocetine,
PDE3 inhibitor; inhibited by: zaprinast Ki 5 35 mm [56]
a Denote number of genes in the family; in parentheses number of known isoforms
b In parentheses are frequently used alternative abbreviations
c Species origin of isoforms is not specified; the most frequent species designations are: human, HS (homo sapiens); rat, RN (ratus norvegicus); mouse, MM
(mus musculus); bovine, BT (bos taurus); for details, see Fig. 4
Dousa: Cyclic-39,59-nucleotide PDE isozymes34
Fig. 4. Schematic depiction of the general
structure of a PDE isozyme monomer. It con-
sists of an N-terminal domain, central catalytic
core, and C-terminal domain, connected by
hinge regions. The domains are not drawn in
proportion. In particular, the size of the N-
terminal domain is substantially different in
various PDE types [19]. Abbreviations are:
PKA, protein kinase A; PKG, protein kinase
G; PKC, protein kinase C; PDE3IK, insulin-
dependent PDE3B protein kinase.
any of the amino acids enclosed may occupy that posi- binding sites for cGMP or for phosphatidic acid. Several
consensus sequences that are phosphorylation sites fortion.) Furthermore, the central catalytic core contains
two consensus Zn21-binding motifs containing histidines: Ser/Thr protein kinases, another frequent mechanism for
regulation of PDE activity, are located in the N domain,3 mol of Zn21 binds to 1 mol of PDE5 monomer [58].
Even early studies have shown that divalent cations are [10–12]. These include phosphorylation sites for: (1)
Ca21-CaM protein kinase II in PDE1; (2) PKA in PDE1,important cofactors of PDE. For example, the addition
of ethylenediaminetetraacetic acid almost completely PDE3, and PDE4; (3) protein kinase G (PKG) in PDE5;
(4) insulin-stimulated protein kinase (PDE3IK) inabolished activity of PDE from heart [4] or kidney [59],
and the activity was restored by addition of Mg21 [4, 59]. PDE3B; and (5) protein kinase C (PKC) in PDE1 and
PDE6 (Table 1 and Fig. 4) [8–10]. Finally, the N-terminalThe maximum cAMP-PDE activity was achieved at 10
mm or more Mg21 [59]. A similar effect of Mg21 was found regulatory domain of some PDE isozymes, such as rat
PDE4A5A (RNPDE4A5A) [37], also contains Src ho-in recent studies of recombinant PDE4 isozymes [60].
Other specific signature motifs specifically identify cGMP- mology 3 (SH3)-binding motifs [37] that confer to these
PDEs the capacity for noncovalent association with pro-binding domains [10, 11] in several PDE isozyme types:
PDE2 (cGMP-stimulated PDE), PDE5 (cGMP-binding teins of other signaling pathways that contain SH3 do-
mains, such as tyrosine protein kinases of the Src familyPDE), and PDE6 (photoreceptor PDE), where this do-
main is located in catalytic subunits a, a9, and b [9]. [61] or cellular structures such as subunits of nicotin-
amide adenine dinucleotide phosphate (NADPH) oxi-Furthermore, unique and defining for the isozymes of
the PDE3 family is a 44-amino acid insert located within dase [62]. The N-terminal domain contains sites for di-
merization [10, 11], as well as sites for hydrophobicthe catalytic core that is not found in any other PDEs.
In contrast to the central catalytic core, the structure interactions and/or membrane-association sites [11, 25,
33, 35, 36].of the NH2-terminal “regulatory domain” of PDE mole-
cules diverges widely among PDE isozymes and isoforms Experimental maneuvers that delete the N-terminal
regulatory domain from the rest of the molecule, suchin structure and size [17]. The N domain contains se-
quences that are target sites for various modes of regula- as limited proteolysis, result in a many-fold increase of
PDE catalytic activity [10–12, 17, 35]. These findingstion: ligand-binding sites, phosphorylation sites, and sites
for several modes of protein–protein interactions (Fig. 4). support a hypothesis proposing that in a basic ambient
state the N-terminal regulatory domain of PDE exertsThese include binding sites for Ca21-CaM and noncatalytic
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an autoinhibitory effect on the catalytic core domain and procedures are fastidiously avoided, reported results
from such fractionation studies often differ and may bekeeps PDEs in a low-activity state [8, 11, 12]. This feature
is consistent with the notion that in cellulo PDE isozymes different between various tissues and, with respect to a
given tissue, between vertebrate species. Generally, inare present in an inhibited state, and various regulatory
mechanisms, that is, phosphorylation or binding of mod- preparations from myocardium, liver, or adipocytes, a
considerable proportion (,50%) of PDE activities areulators that interact with the N-terminal domain, in most
instances, relieve such autoinhibition and enhance cata- apparently associated with membranes [7, 9], whereas
in preparations from platelets, kidney, smooth muscle,lytic activity of the PDE isozyme [10–12, 17, 63].
The functional significance of the rather small C-termi- or mesangial cells (MCs) [66], the majority (,90%) of
PDE activities are in the cytosol [7, 9].nal domain of PDEs is largely unknown. Perhaps it may
serve some regulatory or localization functions that are As recent studies show, localization of PDE isozymes
within the cell is highly relevant for functions of PDEanalogous to the N-terminal regulatory/localization do-
main. According to a recent report, a mitogen-activated isozymes in situ. Elucidation of the primary structure of
PDE isozymes and the study of cells transfected withprotein kinase (MAPK) can phosphorylate Ser487 in the
C-terminal portion of the PDE4B2B isoform [42], a pos- cDNAs encoding PDEs provided the first precise insights
into interactions of PDEs with intracellular structures.sible point of direct cross-talk between cAMP and
MAPK signaling pathways. Consensus sequences— Such investigations showed that the N-terminal hydropho-
bic region of PDE3 is a likely site for interaction withCAAX—for prenylation are present in the C terminus
of catalytic subunits of PDE6: in the PDE6a subunit for membranes [33] and that the first 25 amino acids in
the N-terminal portion of the PDE4A1A molecule arefarnesylation and in the PDE6b subunit for geranylgera-
rylation, prenyl moieties represent another mode of required for attachment to plasma membranes and Golgi
apparatus [63]. After deletion of this N-terminal, 25-mechanism for anchoring PDEs to membranes [10, 11].
Phosphodiesterase isozyme activities can be regulated amino acid sequence, the membrane-associated enzyme
becomes diffusely distributed in the cytoplasm [63, 67].by hormones that act via genomic mechanism and modu-
late gene expression and de novo synthesis of PDE iso- Catalytic subunits of photoreceptor isozymes of PDE6
are apparently anchored to membranes via posttransla-zyme proteins [12, 40]. For example, follicle stimulating
hormone (FSH), via stimulating cAMP generation, can tionally prenylated subunits, a lipophilic interaction.
Some of the PDE4 isoforms, PDE4A5A [37], and per-induce the synthesis of mRNA encoding “short forms”
of PDE4, such as PDE4D1 and PDE4D2 isoforms [12, haps also PDE4D4 [38] that have SH3-binding domains
[61] in the N-terminal region have the potential to inter-19, 40]. In these responses, cAMP acts as an inducer and
may conceivably act via PKA phosphorylation of cAMP- act with cytoskeletal proteins [68], as well as with pro-
teins involved in signaling [32]. Recent studies indicateresponsive element-binding protein [64]. In studies on
cultured CHO cells, agents that stimulate phosphoinosi- that an isoform(s) of PDE4 from MCs [15] is likely to
interact with SH3 binding domains [69] and also Srctide metabolism and that activate PKC selectively in-
duced expression of PDE1B [28]; the action of growth homology 2 (SH2) domains that allow binding on phos-
photyrosine (T.P. Dousa, M. Beard, M.D. Houslay, C.S.hormone to increase PDE4 isoform PDE4A5 probably
involves stimulation of p7056 kinase [65]. The up-regula- Chini, H.I. Walker, preliminary observations). Protein–
protein interactions that involve SH3 and SH2 may betion of PDEs via a genomic mechanism is a basis for
long-term desensitization to effect of hormone-agonists, important for the localization of PDEs in the cell as well
as for cross-talk with other signaling pathways [8, 38].such as FSH [10, 40]. In contrast, some increases of PDE
isozyme activities, with fast onset, are due to Ser/Thr
Differential expression of PDE isozymesphosphorylations of a site within the N-terminal domain
in cells and tissuesand are a likely basis for a short-term negative feedback
or desensitization of cells to action of hormones that The expression and precise location of PDE isozymes
and PDE isoforms in a number of cell types and tissuesstimulate cAMP synthesis [8, 11, 12, 33].
have been recently determined, mainly with the use of in
Intracellular localization of PDE isozymes situ hybridization and by immunohistochemical methods
[10, 11]. For example, Reinhardt et al mapped the distri-Phosphodiesterases are not intrinsic membrane pro-
teins but are often associated, loosely or tightly, with bution of two isozymes, PDE3A and PDE3B, in major
rat tissues [70]. Discovery of the unique expression ofmembranes [8, 10, 11, 35, 63]. The association of PDE
isozymes with membranes is sometimes difficult to deter- PDE2 in cells of the zona glomerulosa of the adrenal
gland [30] contributed to the delineation of the signalingmine with certainty with use of standard subcellular frac-
tionation techniques [7], as much depends on the method pathway by which atrial natriuretic peptide (ANP) acts
to inhibit synthesis of aldosterone. In glomerulosa cells,for disruption of the tissues or cells by mechanical forces
or detergent treatment [7]. Even when gross disruptive ANP increases cGMP synthesis. Increased cGMP stimu-
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lates cAMP breakdown by PDE2A1, and the resulting should be interpreted with caution. Extracts from rat
myocardium contain several PDE types, including PDE1decrease of cAMP is a signal to decrease aldosterone
synthesis and secretion [30]. Studies of the central ner- [75]. However, similar extracts prepared from isolated
rat cardiomyocytes show analogous PDE patterns, butvous system showed that high activity of PDE1B is con-
centrated in basal ganglia, and its presence correlates without PDE1 activity, thus suggesting that PDE1 is
likely contained in cells other than myocytes, for exam-with sites of dopaminergic innervation [71]. Yan et al
determined the localization of splice variants of several ple, fibrocytes [75].
Differential expression of PDE isozymes and isoformsPDE1C isoforms (PDE1C1 to PDE1C5) in mouse tis-
sues, particularly in the brain, olfactory epithelium, and is a critically important determining factor that adds to
great fundamental diversity of the cell-specific PDE iso-testis [29]. In this context, it should be stressed that
detection of cognate mRNA by the in situ hybridization zyme systems. In principle, signal transduction via cyclic
nucleotide systems in a given cell type is determined bytechnique alone may give only partial information about
the presence and function of the PDE isozyme. In studies (a) the expression of specific cell-surface receptors for
hormones, neurotransmitters, or autacoid that is cou-of isozyme PDE7A1, abundant mRNA was detected
with use of in situ hybridization technique in muscle pled, positively or negatively, to adenylate cyclase or is
part of guanylate cyclase, and (b) the pattern of PDEtissue, T lymphocytes, and B lymphocytes [51]. However,
the catalytic activity of both PDE7 and immunoreactive isozymes and isoforms that is expressed to a different
degree. PDE isozymes thus confer to cAMP and cGMPprotein was found in only T-cell lymphocytes; little or
no immunoreactive protein or enzymatic activity was signaling pathways, in a given cell, a second crucial point
that determines specificity of signal transduction, which,found in B lymphocytes and in muscle [51]. Such findings
illustrate that quantitatively high expression of cognate together with receptors and cyclases, define the “cyclic
nucleotide signaling phenotype” of a particular cell typemRNA in the cell does not necessarily indicate the pres-
ence of high activity of a translated and active PDE [10].
isozyme. Possibly, in some cell types, mRNA of PDE is
not translated or the translated protein is either inactive
CHARACTERISTICS OF PHOSPHODIESTERASEor unstable, and conceivably the expression of some PDE
ISOZYME FAMILIES (TYPES)isozymes might be regulated at the translational level
The key properties of seven known gene families[51].
(types) of PDE isozymes are concisely outlined here andThe expression of PDE isozymes may depend on the
are summarized in Table 1.biologic state and environment of the cell. For example,
freshly isolated circulating monocytes/macrophages show
PDE1 familyhigh activity of PDE4 but little or no other PDEs, whereas
The PDE1 family (Ca/CaM-stimulated PDE) is amonocytes/macrophages that reside in tissue, such as
group of isozymes that are dependent for their activitypulmonary alveolar macrophages, express less PDE4
on Ca21 and CaM. The binding site for CaM/Ca21 isthan circulating monocytes but have high PDE3 activity
positioned close to the N terminus of the regulatoryand very high activity of PDE1 [72, 73]. When isolated
domain [10, 19]. The PDE1 isozyme family, along withmonocytes are grown in cell culture, they assume the
the PDE4 family, is the most diverse and includes numer-same PDE isozyme pattern as alveolar macrophages [72,
ous splice-variant PDE isoforms, such as PDE1C1–5 [29].73]. Diverse expression of PDE1 isozymes is well docu-
Products of two genes, PDE1A and PDE1B, have highermented in a study of vascular smooth muscle [74].
affinity for cGMP than for cAMP, but some isoforms ofWhereas freshly prepared quiescent human aortic vascu-
PDE1C exhibit also high affinity for cAMP [10]. Further-lar smooth muscle cells contain isozymes PDE1A and
more, activities of PDE1 isozymes are modulated by Ser/PDE1B, in proliferating smooth muscle cells, which are
Thr phosphorylations of sites Ser131, Ser143 located in thegrown in primary culture, PDE1C is the dominant iso-
N-terminal domain. PDE1A1 from heart and PDE1A2zyme [74]. Moreover, cultured vascular smooth muscle
from brain are phosphorylated by PKA, whereas PDE1Bcells from monkey aorta have highly expressed PDE1B
is phosphorylated by CaM-dependent protein kinase II,but no PDE1C; PDE1A was the only detectable PDE1
and all of these phosphorylations can be reversed by cal-isozyme in vascular smooth muscle cells grown from rat
cineurin, a Ca/CaM-dependent phosphatase [20]. Bothaorta [74]. Clearly, the expression of PDE1 isozymes
types of phosphorylation decrease the affinity of PDE1depends on the status of the cell cycle and also differs
for CaM and increase Ka for Ca21 activation. Accordingbetween species [74]. The two members of the PDE3
to a recent report, PDE1B can be induced by activationfamily, PDE3A and PDE3B, are subject to develop-
of protein kinase C (PKC) or transfection with PKC-amental regulation of gene expression [70]. Results of
or PKC-e [28]. Thus, PDE1 isozymes have potential forstudies when the PDE pattern is determined in extracts
from whole tissues or heterogeneous cell populations cross-talk with several other signaling systems that in-
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clude, at least, Ca21 and CaM, Ca21/CaM-dependent pro- pure cAMP-PDE [10, 11, 33, 64]. Products of two iso-
genes, PDE3A and PDE3B, differ in their distributiontein kinases and phosphatases, and cAMP-PKA and
PKC pathways. Any compounds that chelate Ca21 or in organs and tissues [70], as well as in their regulation
[11, 33]. PDE3A is more sensitive to inhibition by cGMPinhibit CaM activity act as effective inhibitors of PDE1
but have many other effects. Some selective inhibitors than is PDE3B. Both subtypes, PDE3A and PDE3B,
are activated by Ser/Thr phosphorylation on Ser302 in theact directly on the catalytic site of PDE1 isozymes, such
as 8-methoxymethyl-IBMX (8-MeoM-IBMX) and vin- N-regulatory domain, which is catalyzed by PKA [33].
In addition, PDE3B is activated by phosphorylation ofpocetin [7, 9, 76]. PDE1 isozymes are present in many
tissues and are abundant mainly in the central nervous the same site, Ser302, which is catalyzed by the insulin-
stimulated protein kinase of PDE3 (PDE3IK) [33]. Al-system, heart, and kidney.
though the insulin-dependent phosphorylation and acti-
PDE2 family vation of PDE3B catalyzed by PDE3IK is amply docu-
mented [33], the whole sequence of steps in the signalingIn the PDE2 family (cGMP-stimulated PDE, cGs-PDE),
as well as in the case of PDE1, both cAMP and cGMP mechanism by which insulin, after interaction with its
receptor, leads ultimately to activation of PDE3IK is notare substrates for PDE2, which is specifically stimulated
by cGMP with positive cooperativity kinetics [10, 11]. yet clarified, but it is likely that an essential step in this
pathway involves activation of phosphatidylinositol-3 ki-In the PDE2 molecule, the two specific, noncatalytic
cGMP-binding sites are located in the N-terminal regula- nase [33]. Thus, PDE3 is a target for negative cross-talk
with cGMP pathways and positive cross-talk betweentory domain, upstream of the conserved central core.
Hydrolysis of both cAMP and cGMP is stimulated by insulin, as well as cAMP signaling pathways. It is postu-
lated that phosphorylation of PDE3A or PDE3B bycGMP; PDE2 has a rather low affinity (Km > 10 mm) for
both cAMP and cGMP. Three PDE2 isoforms, probably PKA probably represents a short-term negative feed-
back regulation. Both PDE3A and PDE3B are sensitivesplice variants, have been described: the cytosolic PDE2A1
enzyme in adrenal cortex [30], the PDE2A2 isoenzyme to inhibition by numerous synthetic inhibitors, including
many “cardiotonic inhibitors,” which are effective in lowin membranes from brain and cardiac tissue [31], and
most recently, isoform PDE2A3 [32]. The PDE2A2 iso- micromolar concentrations. The experimental and clini-
cal use of PDE3 inhibitors was extensively investigated,form has a hydrophobic region in the N-terminal domain
that likely accounts for membrane targeting [31]. Be- and some, such as cilostazol [81] or milrinone [82], are
used in clinical practice.cause PDE2 was found in cells that express little or no
PKG, PDE2 is considered to be one of the main recep-
PDE4 isozymestor targets for cGMP in some cGMP-mediated signal-
transduction mechanisms, and represents a classic site of Phosphodiesterase 4 isozymes (cAMP-specific PDE;
cAMP-PDE) are the most diverse family of PDEs andcross-talk between cAMP and cGMP signaling pathways
[8, 10]. The only known selective inhibitor of PDE2 is hydrolyze selectively and with high affinity only cAMP.
Therefore, PDE4 is also sometimes referred to aserythro-9-(2-hydroxyl-3-nonyl)-adenine (EHNA), which
is also a potent inhibitor of adenosine deaminase [77]. “cAMP-specific PDE” [12]. PDE4 isozymes consist of
four subfamilies (subtypes) encoded by isogenes PDE4AThus, when employed as a PDE2 inhibitor, EHNA ought
to be compared with the effect of a structurally unrelated to PDE4D, which in turn are transcribed and expressed
in numerous splice-variant PDE isoforms [10–12]. Splice-adenosine deaminase inhibitor that does not inhibit PDE2,
such as 19-deoxycoformycin [78]. EHNA has positive ino- variant isoforms of PDE4 are distinguished by the struc-
ture in the N-terminal domain, which confers diversetropic [78] and thrombostatic [79] effects that are related
to inhibition of PDE2. Some analogues of cGMP that are regulatory properties and capacity for interactions with
other cell structures [37, 35, 39, 46, 63, 67]. Some iso-often used to mimic cGMP effects, namely C 8-substituted
compounds, 8-pCPT-cGMP, or 8-Br-cGMP do not stim- zymes of PDE4 can be up-regulated by cAMP via two
different mechanisms. “Short isoforms” (less than 72ulate PDE2 [80] and cannot be used for probing this
isozyme. kDa), such as PDE4D1 or PDE4D2, are subject to long-
term up-regulation by cAMP via a transcriptional control
PDE3 isozymes mechanism [8, 12, 40, 41, 43, 45]. An increase in the
cellular cAMP level enhances synthesis of cognatePhosphodiesterase 3 isozymes (cGMP-inhibited PDE)
display high affinity for both cAMP and cGMP but have mRNA and de novo synthesis of the enzyme molecules
[12, 40, 41, 45, 83], and the induction can be blockeda far higher Vmax for cAMP than for cGMP [11, 33, 64].
cGMP in micromolar concentrations binds to the cata- by actinomycin D and cycloheximide [84]. Interestingly,
elevation of cAMP in T cells resulted in an induction oflytic site of PDE3 and thereby competes with cAMP
hydrolysis; however, because of the low Vmax, cGMP hy- PDE4D and a simultaneous decrease of PDE4A [84].
In a monocytic cell line, U937 increased cAMP-enhanceddrolysis by PDE3 is negligible, and PDE3 behaves as a
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expression of PDE4A and PDE4B, whereas expression gers within the catalytic core domain of PDE5. Only one
gene is known so far, and some observations suggest thePDE4D apparently decreased [85].
On the other hand, “long isoforms” of PDE4D (more existence of two splice variants [11]. PDE5 is inhibited
selectively by zaprinast and dipyridamol [95]; novel in-than 93 kDa), such as PDE4D3, are activated by a cAMP-
reversible phosphorylation of Ser54, which is located within hibitors with higher affinity (Ki ,1 nm) include E4021
[96], sildenafil [97], WIN58237 [95], or DMPPO [98].the “upstream conserved region” UCR1 close to the
N terminus that is catalyzed by PKA [47]. This phosphor-
PDE6 isozymesylation causes a rapid, several-fold increase in catalytic
activity of PDE4D3 and also greatly increases (more The PDE6 isozymes (photoreceptor PDE) family are
heterotetramers or homotetramers composed of varia-than 100 times) the sensitivity of PDE4D3 to the selec-
tive inhibitors rolipram or compound RS-33793 [86, 87]. tions of catalytic subunits (a, a9, b) and inhibitory sub-
units (g and d) [10, 11, 19, 49]. PDE6 isozymes are ex-Some isoforms, such as PDE4A4B, become more sensitive
to rolipram when associated with membranes, and the pressed solely in retinal rods and cones and have a highly
specialized function in photoreceptor signaling [10, 11,kinetics of the inhibition also change [88]. Another bioreg-
ulator is phosphatidic acid, which activates PDE4D3, 19, 49]. PDE6 is a pivotal step in a pathway initiated by
photons that interact with rhodopsin, which is coupledprobably via binding on N-terminal domain [48]. It is
postulated that up-regulation of PDE4D isoforms by via the heterotrimeric G-protein “transducin” to mem-
brane-associated PDE6, and results in increased PDE6cAMP via different mechanisms is a basis for long- and
short-term desensitization of cell responses to increased activity by causing dissociation of inhibitory g subunits
from catalytic subunits. Activation of PDE6 then resultssynthesis of cAMP, as it is exemplified by desensitization
of Sertoli cells to FSH or thyroid epithelial cell line to in a drop in cGMP levels and an opening of the cGMP-
gated ion channel [11, 19, 49]. The termination of thethyroid-stimulating hormone [12, 40, 83, 89].
Archetypal selective inhibitors of PDE4 are rolipram activated state of PDE6 involves reassociation of g sub-
units with catalytic PKC [11]. PKC may phosphorylateand Ro 20-1727. However, recently a number of newer
PDE4 inhibitors that display up to 1000 times higher the g subunit on Thr35 and thereby increase its inhibitory
activity [11]. Kinetic and catalytic properties and sensitiv-affinity for PDE4 (,1 nm) than rolipram (,1 mm) [8,
44, 90, 91] have been synthesized [8, 90–92]. Rolipram ity to inhibitors of PDE6 isozymes closely resemble iso-
zymes of the PDE5 family; however, substantial differ-binds with a very high affinity (1 nm) to PDE4 isozymes
at the site that is probably within the core catalytic do- ences in primary structure and subunit composition, as
well as its highly specialized function, distinguish PDE6main [43, 44]. The relationship of these “high affinity
rolipram-binding sites” (HARBS) [44] in the PDE4 mol- from the PDE5 family [10, 11, 19].
ecule to the inhibitory action of rolipram on cAMP hy-
PDE7 isozyme familydrolysis is not clear [43, 44, 90–92]. Rolipram that is
bound to HARBS can be displaced competitively by Recently the PDE7 isozyme family (HCP1) was dis-
covered. PDE7 was cloned, expressed, and identified ascAMP; however, recent studies indicate that HARBS
are not identical with the catalytic site for cAMP in the a new PDE family that is genetically distinct from others
[50]. The known characteristics of PDE7 include highcatalytic core of PDE4 [43, 44]. It is believed that
HARBS relate to some of the pharmacologic effects of affinity and selectivity for cAMP as a substrate, similar
to that of PDE4. Importantly, PDE7 isozyme differsPDE4 inhibitors that are unrelated to inhibition of
cAMP hydrolysis, namely emetic action and gastric acid significantly from PDE4 and PDE3 by its lack of sensitiv-
ity to inhibition by cGMP, by inhibitors of PDE4 roli-hypersecretion [44]. Several novel inhibitors of PDE4
have a higher affinity for PDE4D than for PDE4A, pram and RO 20-1724, PDE3 inhibitor enoximone,
PDE2 inhibitor EHNA or PDE5 inhibitor zaprinast [50–PDE4B, and PDE4C [43, 44].
Phosphodiesterase 5 isozymes (cGMP-binding PDE) 52]. Also, PDE7 is apparently relatively insensitive to
inhibition by nonselective IBMX [28, 99]. Cognateare abundant in lung, platelets, and smooth muscle [10–
12]. PDE5 isozymes are strictly specific for cGMP and mRNAs encoding PDE7 were isolated and found ex-
pressed in a number of tissues, including kidney [50–52],are characterized by the presence of two high-affinity
noncatalytic cGMP-binding sites in the N-terminal do- and two isoforms-splice variants, PDE7A1 and more
recently PDE7A2 [51, 52], have been identified. Isoformmain [5, 10, 11, 93]. Binding of cGMP to PDE5 by itself
does not influence PDE activity but results in a confor- PDE7A2 has a hydrophobic sequence in the N terminal
and is, at least in part, membrane bound [52].mational change of the PDE5 molecule that facilitates
phosphorylation by PKG [10, 93] and possibly also by
PDE8 isozymesPKA [94], both of which are associated with the up-
regulation of PDE5 activity [93]. Furthermore, PDE5 is The PDE8 isozyme family of isozymes was recently
cloned from human [53] and murine tissues [54], andactivated by Zn21 ions, which probably bind to zinc fin-
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enzymes expressed in transfected cells were examined. artifacts [9, 18, 83]. It is now known that when working
with cell-free preparations from tissues or cells, all proce-PDE8 is cAMP specific and has a very high (so far the
highest) affinity for cAMP as a substrate: , 20 times dures ought to be carried out in the presence of a mixture
of protease inhibitors, calcium chelators and sulfydryl-lower KmcAMP than PDE4. However, it has approximately
10-times lower Vmax than PDE4 [53]. Another specific reducing reagents, and other agents that minimize prote-
olysis, as well as to fastidiously keep the temperature atfeature of PDE8 is its insensitivity (at 100 mm or more)
to cGMP, to the PDE4 inhibitor rolipram, the PDE5 0 to 48C. Fractionation and isolation procedures that are
based on charge and size, affinity to cyclic nucleotides,inhibitor zaprinast, the PDE1 inhibitor vinpocetine, and
the PDE3 inhibitor SKF-94120, as well as to the nonse- modulators, antibodies, and PDE inhibitors preferably
should be carried out with rapid separation techniques,lective inhibitor IBMX [53, 54]. Surprisingly, PDE8, a
cAMP-hydrolyzing enzyme, is inhibited by dipyridamole such as biocompatible high pressure liquid chromatogra-
phy (HPLC) or fast protein liquid chromatography(IC50 5 9 mm), a compound that specifically inhibits
PDE5, an isozyme that is known to hydrolyze only cGMP (FPLC) systems. PDE isozymes are more stable when
stored at 2208C in a non-solid frozen state in a medium[7, 9–11]. Human [53] and murine [54] PDE8 isozymes
are quite similar. Analysis of mRNA encoding PDE8 containing 30% ethylene glycol, which prevents freezing
[101, 102]; this storage method is often superior to rapidindicates that this isozyme is abundant in numerous ex-
amined tissues, most prominently in testis, ovary, and freezing and storage at 2708C. Finally, methods of mo-
lecular cloning and recombinant DNA technologies inintestine [53, 54].
the study of PDE isozymes are similar to those used in
PDE9 isozymes other areas of investigations.
Unique experimental tools are selective PDE isozymeThe PDE9 isozyme family was discovered almost si-
multaneously with PDE8; however, it has profoundly inhibitors that are used for probing PDE isozymes, and
their function in vitro and especially in vivo should bedifferent characteristics [55, 56]. PDE9 hydrolyzes spe-
discussed in more detail. Of equal importance is thecifically cGMP, not cAMP [55, 56]. Further, compared
potential of PDE inhibitors to become unique novelwith other cGMP-specific PDEs, PDE9 apparently lacks
pharmacologic agents [7–9]. Availability of PDE iso-noncatalytic cGMP-binding domain, which is present in
zyme–selective inhibitors and identification of their spe-PDE5, PDE6, and also in molecules of PDE2 [5, 10, 11,
cific biomodulators are of singular importance for the93]. As it is the case of PDE7 and PDE8, the activity of
study of PDE isozymes in cell-free systems and evenPDE9 is insensitive to nonselective inhibitor IBMX [55,
more so for studies of PDE isozyme functions in cellulo.56] and is also resistant to selective inhibitors of PDE1,
PDE2, PDE3, PDE4, and PDE5 [55, 60]. The only com-
Overview of PDE inhibitorspounds identified to date that inhibit the activity of PDE9
Nonselective inhibitors. Even in the initial phases of[55, 56] is zaprinast (IC50 ,30 mm), an inhibitor that was
PDE research, it was determined that several commonpreviously considered to be selective for PDE5, and even
alkaloids, including methyl xanthines theophylline, theo-more potent, on a molar basis, is SCH518866 [55], a
bromine, and caffeine, as well as the isoquinoline deriva-compound that inhibits both PDE5 and PDE1 [100].
tive papaverine, which have been widely used as pharma-The mRNA encoding PDE9 is well expressed in many
ceuticals in clinical practice, were identified as PDEexamined human tissues, including spleen, small intes-
inhibitors, compounds that specifically inhibit the activitytine, and brain [56]. Expression of mRNA encoding mu-
of PDE and not other phosphohydrolases [4, 7, 9, 102,rine PDE9 is very prominent in the kidney and far less
103]. These PDE inhibitors inhibit PDE competitivelyin other examined tissues [56].
with low affinity (Ki > 1 mm) and do not discriminate
between PDE isozymes; both cAMP-PDE and cGMP-
STUDY APPROACH TO PDE activities are inhibited [4, 103]. Nonselective PDE
PHOSPHODIESTERASE ISOZYMES inhibitors are currently referred to as “first-generation
AND THEIR INHIBITORS PDE inhibitors” [7, 9, 103, 104]. Besides their low affinity
Except for a few specific features mentioned herein, for PDEs, the “first-generation” PDE inhibitors often
the biochemical, cellular, and molecular biologic meth- have pharmacologic effects unrelated to the inhibition
odologies for the investigation of PDE isozymes do not of PDE. Theophylline and other methyl xanthines are
differ from those used to study other enzyme systems. potent antagonists of adenosine receptors [7, 9, 104];
In the course of studies about PDEs, it became evident caffeine can trigger or potentiate Ca21 release from en-
that PDE isozymes are proteins very susceptible to pro- doplasmic or sarcoplasmic reticulum through the rya-
teolytic attack. Consequently, many past studies aiming nodine receptor channel [105]; and papaverin blocks
to enrich and isolate PDEs, using the then standard pro- adenosine uptake [103]. One methylxanthine derivative,
IBMX, which was synthesized by Wells et al [106], hastein isolation techniques, very likely produced numerous
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a much higher affinity (Ki > 1–10 mm) for PDEs and in should be carefully chosen to maximize specificity and
selectivity of these pharmacologic probes [7, 9, 10, 23,low concentrations preferentially inhibits cGMP-PDE
over cAMP-PDE [9–11, 106]. IBMX became a popular 26]. It should also be kept in mind that some second-
generation PDE isozyme–specific inhibitors may haveand frequently used experimental tool and is widely em-
ployed in experimental studies to suppress cyclic nucleo- effects on other cellular functions that are unrelated to
PDE. Compounds, such as antagonists of CaM or Ca21-tide breakdown by PDE. Recent advances in PDE re-
search indicate that previously assumed nonselectivity chelating agents, do selectively inhibit PDE1 as also do
other Ca21/CaM-dependent enzymes and membraneof IBMX is not universal. A PDE activity insensitive to
IBMX was found in a fraction of rat liver homogenate channels. EHNA, the only known selective inhibitor of
PDE2, was first known as a potent inhibitor of adenosine[107]. Newly identified PDE types, cAMP-specific PDE7
and PDE8, and cGMP-specific PDE9 are resistant to deaminase [77]. Dipyridamole, a compound that inhibits
specifically PDE5, PDE6, and PDE8, also blocks trans-inhibition by IBMX at 0.1 mm or less. These novel find-
ings may explain why, even with maximum inhibitory port of adenosine [7], and the methyl xanthine derivative
denbufylline, a selective inhibitor of PDE1 [7], is also anIBMX concentration, certain cAMP-PDE and cGMP-
PDE cannot be suppressed [35, 107]. This “residual activ- adenosine receptor antagonist. The existence of effects
unrelated to PDE does not preclude these compoundsity” of PDE [73] found in tissue extracts is likely caused
by activities of PDE7, PDE8, and PDE9, which are ex- from being used as selective PDE isozyme inhibitors,
providing that these side effects are kept in mind inpressed in numerous tissues. This new information
should be kept in mind when interpreting experiments interpreting the results and when appropriate controls
are included in the experimental design.with the use of IBMX, both in cell-free systems and in
intact cells. Despite obvious limitations, “first-genera- Phosphodiesterase inhibitors that discriminate be-
tween PDE isozymes that are products of a single isogenetion” PDE inhibitors were very helpful in probing
cAMP-mediated actions, especially in intact cells. In fact, (such as PDE subfamilies or PDE subtypes) within one
gene family, or even discriminate between splice variantsone of Robison et al’s four criteria [108] to determine
whether hormonal response is mediated by cAMP in- of PDE isoforms (the putative “third-generation” PDE
inhibitors) have yet to be developed. However, becausecludes the requirement that the observed functional re-
sponse is synergistically enhanced by the addition of of intense efforts by many pharmaceutical drug-discov-
ery groups, such PDE inhibitors may soon become avail-PDE inhibitors [108]. These inhibitors continue to be
widely used in clinical practice. able. In fact, some novel inhibitors of PDE4 show some
degree of selectivity for PDE subtypes. For example,Isozyme-selective PDE inhibitors. Over the last 15
years, the search for more potent PDE inhibitors yielded compound CP77059 inhibits subtype PDE4D to approxi-
mately a tenfold greater degree than PDE4A, PDE4B,a large number of compounds that were synthesized or
identified as novel PDE inhibitors. These compounds and PDE4C [43]. Another novel compound, RS33793,
displays high potency and selectivity for the “long” iso-have higher affinity (Ki # 1 mm) for PDEs than nonselec-
tive inhibitors and, even more importantly, show selectiv- form PDE4D3 when it is phosphorylated by PKA;
RS33793 inhibits phosphorylated PDE4D3 with approxi-ity for various gene families (types) of PDE isozymes
[7, 9, 17, 23]. These “second-generation” PDE inhibitors mately 300 times greater potency than in the dephos-
phorylated state [86, 87]. This observation indicates that[7, 9, 17] do exhibit about 100-fold selectivity for PDE
isozymes of a particular type (family), as assessed by the sensitivity of PDE subtypes and isoforms to selective
PDE inhibitors may depend on the functional/biochemi-IC50 when measured under comparable conditions [10].
To date, second generation, type-selective PDE inhibi- cal state of PDE isozyme and hence on the conditions
of testing.tors have been found or developed for selective inhibi-
tion of PDE1, PDE2, PDE3, PDE4, and PDE5 (Table Several selective PDE inhibitors that act simultane-
ously on two distinct PDE isozymes are referred to as2). Photoreceptor PDE6 is sensitive to the same selective
inhibitor as PDE5, whereas no specific inhibitor of PDE7 “hybrid,” “combination” or “dual” inhibitors [10, 137,
138]. Such inhibitors were developed based on the notionhas yet been found [50–52, 99]. Most “second-genera-
tion” PDE inhibitors identified to date are selective for that simultaneous inhibition of two PDE isozymes has
a synergistic pharmacologic effect [137]. The most com-PDE3 or PDE4 [7, 9–11, 33, 34, 44, 92].
Even these type-selective PDE inhibitors are not abso- mon dual inhibitors simultaneously block the activities
of both PDE3 and PDE4, PDE3/4 inhibitors [137, 138],lutely specific, particularly at higher concentrations. For
example, zaprinast at lower concentrations inhibits selec- and were developed with the aim of suppressing two
major pathogenic components of bronchial asthma: in-tively PDE5, and at higher concentrations, it inhibits
also PDE1 [95, 136] and newly discovered PDE9. There- flammation and bronchoconstriction [26, 44, 90–92].
Dual PDE4/5 inhibition was observed with WIN58237fore, in designing experiments with the use of such inhibi-
tors, the proper concentration and other conditions [95]; dual PDE1/5 inhibition with zaprinast [95] and dual
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Table 2. Second-generation PDE isozyme inhibitors and their pharmacologic properties
PDE type Pharmacotherapeutic applications,
(family) Inhibitory compounds Pharmacologic actions experimental and clinical
PDE1 vinpocetine nootropic Dementia, memory loss [109, 110]
8-MeoM-IBMX
PDE2 EHNA (MEP-1) inhibits platelet aggregation
increases L-type Ca21 current in heart
PDE3 milrinone, vesnarinone, inotropic Congestive heart failure [34, 82, 111, 112]
cilostazol, cilostamide vasorelaxation thrombosis [113, 114]
(and many others) antithrombotic pulmonary hypertension [115, 116]
antiproliferative glomerulonephritis [117, 118]
PDE4 lower affinity: (Ki . 1 mm) antidepressive Bipolar depression [119, 120]
rolipram, Ro-20-(724) immunosuppressive bronchial asthma [27, 92, 121]
denbufylline anti-inflammatory atopic diseases [122, 123]
high affinity: (Ki . 1 nm) (suppress superoxidation and generation autoimmune enceptholomyelitis [124, 125]
CDP 840 of TNFa, IL-1b, INFg) organ transplantation [126–129]
RP 73401 smooth muscle relaxation
CP 80, 633, RS 33793
PDE5 zaprinast (M&B 22,948) vasorelaxation, natriuretic, antithrombotic Pulmonary hypertension [130, 131]
dipyridamole salt retention in nephrotic syndrome [132, 133]
E-4021, WIN 58237 erectile dysfunction [97, 134]








PDE3/5 inhibitors have recently been reported [95]. as valuable tools for in vitro and in vivo investigations
Some inhibitors that were until recently considered spe- of the PDE superfamily’s function. Enhancement or po-
cific (or at least relatively specific) for one PDE type tentiation of tissue response to hormones and autocoids
turned out to be “hybrid” inhibitors. Dipyridamole, al- by first-generation PDE inhibitors was one of the key
ready known as a potent and specific inhibitor of cGMP- criteria proving that the response is mediated by cyclic
specific isozyme PDE5 [10, 11, 96], also was shown to nucleotides [108].
inhibit newly discovered cAMP-specific isozyme PDE8 Selectivity for second-generation PDE inhibitors is so
[53, 54]. Compound SCH 51866, a dual inhibitor of PDE1 prominent that when used in the proper experimental
and PDE5 [100], turned out to inhibit also PDE9 [55], design, the effects of these inhibitors could be considered
and in view of this, it may be considered a “triple” PDE “diagnostic” for detecting the presence of PDE isozyme
inhibitor. Although the rationale for the usefulness of (types) in cells and tissues, or for their involvement in
such compounds remains to be seen, it is arguable functional responses that are mediated by cyclic nucleo-
whether dual inhibitors with fixed ratio of activities can tides in vivo and in vitro [7, 9, 72, 73]. Two or more
be superior to combination of two monospecific PDE selective PDE inhibitors of distinct chemical structure
inhibitors that can be administered in various ratios of ought to be used, whenever feasible, as probes in such
doses to yield optimum pharmacologic effects.
experiments.According to several reports, some selective PDE in-
With the use of PDE isozyme inhibitors and activatorshibitors can suppress to a different extent the activities
of PDE modulators, it is possible to detect the presenceof the same PDE isozyme isolated from different tissues.
of PDE isozymes even in crude cell-free preparationsThe PDE3 inhibitor vesnarinone had approximately 10-
[9, 73]. When PDE activities are measured in cell homog-times higher potency to inhibit PDE3 from heart or kid-
enates or in a fraction of the homogenate, the effect ofney than PDE3 from other organs [139]. Gensenoside
a PDE isozyme–selective inhibitor indicates the presencederivatives inhibit PDE1A from myocardium but not
of PDE type; maximum inhibition can approximate thePDE1B from brain [140].
abundance of the PDE isozyme [9, 73]. Such analysis
PDE inhibitors as experimental tools and drugs of cAMP-PDE isozymes is schematically illustrated in
Figure 5. Maximum inhibition of cAMP-PDE activity byFrom the very inception of cyclic nucleotide research,
PDE inhibitors, both nonspecific and selective, served selective PDE3 and PDE4 inhibitors approximates the
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and PDE5, that is, activities in the absence of added Ca21/
CaM or cGMP. In an analogous manner, the specific
activators Ca21/CaM and cGMP are used to determine
PDE1 and PDE2 activities, respectively (Fig. 5B). Selec-
tive inhibitors may also be used. Direct inhibitors of
PDE1, such as vinpocetine or 8-MeoM-IBMX, suppress
not only the Ca21/CaM-dependent component but also
basal activity of PDE1. When activity of some PDE
isozyme type is not detected using this approach, the
results should be interpreted with caution. Possibly, the
optimal conditions for detecting the PDE isozyme activ-
ity such as substrate concentration or cofactors might
not have been employed. Moreover, activities of some
PDE isozymes may depend on conditions such as the
state of phosphorylation [11, 26, 33, 44, 86, 87]. If both
PDE2 (stimulated by cGMP) and PDE3 (inhibited by
cGMP) isozymes are present in comparable activities,
no net effect of added cGMP on cAMP-PDE activity
would be apparent [9]. Needless to say, the presence of
PDE isozymes determined with the use of inhibitors and
activators ought to be confirmed by direct methods. With
these qualifications kept in mind, probing with selective
inhibitors and modulators is a most useful approach for
initial assessment of PDE isozyme patterns in unex-
plored cells or tissues [9, 72, 73]. Exploration of the PDE
isozyme pattern in extracts from nephron segments and
cultured renal cells showed diverse expression of PDE
isozymes (Table 3). Sensitivity to selective PDE isozyme
inhibitors and modulators is also used for characteriza-
tion of PDE isozymes in fractions of cell tissue extracts
obtained by chromatography and other separation meth-
Fig. 5. Example of an experimental design to detect and assess PDE ods [7, 101].
isoenzymes semiquantitatively in a tissue extract, using selective PDE Selective PDE isozyme inhibitors are also employedinhibitors and biomodulators. The values of cAMP-PDE activity and
in principle, using a similar approach in studies of thecAMP-PDE activity in the absence of modulators or inhibitors is taken
as 100%. (A) PDE inhibitors. The PDE3 activity and PDE4 activity whole cell in vitro to identify functions that are regulated
are assessed by inhibiting cAMP-PDE with maximum dose of the PDE3- by cAMP-PKA pathways and linked to a specific PDEselective inhibitor cilostamide, and PDE4 by inhibition with the selective
isozyme(s). Various preparations, such as freshly isolatedinhibitor PDE4 rolipram. When added together, the effects of both
inhibitors are additive. The “residual activity,” not sensitive to inhibition cells or cells grown in culture, tissue slices, etc., are incu-
by cilostamide and rolipram combined, may reflect, in part, PDE7 or bated in vitro with PDE isozyme inhibitors alone or withPDE8 (which are insensitive to these inhibitors), as well as basal activi-
adenylate cyclase stimulated either directly by forskolinties of PDE1 and PDE5 (activities measured in the absence of added
Ca21/CaM or cGMP. (B) PDE biomodulators. PDE2 is determined by or by agents that act to cyclase-coupled receptors. The
the cAMP-PDE activity sensitive to maximum stimulation by added effect on cAMP content, in situ activity of PKA deter-cGMP, and PDE1 is activity of cGMP-PDE maximally stimulated by
mined by the (2 cAMP/1 cAMP) PKA activity ratio,Ca21 with calmodulin (CaM). Maximum effective concentrations of
inhibitors and modulators are based on dose–response curves. and the specific cellular functions are determined. Using
this strategy, for example, we found that in glomerular
mesangial cells (MCs), a PDE3-linked cAMP pathway
suppresses mitogenesis, whereas cAMP-PKA linked to
relative proportion of the two PDE isozymes in the cell PDE4 selectively modulates reactive oxygen metabolite
extract (Fig. 5A). The “residual activity” that remains (ROM) generation (Fig. 6) [15, 66, 143]. Signal transduc-
after maximum inhibition with PDE3 and PDE4 inhibi- tion via cGMP pathways is probed in an analogous man-
tors combined (which are additive) is likely due, at least ner, except that measurement of in situ activation of
in part, to activity of PDE7, an isozyme that is specific PKG is not applicable in cellular responses when cGMP
for cAMP and is not sensitive to the inhibitors of PDE4 acts directly on an ion channel or PDE2 [3]. In the pres-
and PDE3 [51, 52, 73], and is relatively insensitive to ence of PDE isozyme inhibitors, the activity of the cAMP
PKA pathway is increased even in a state when adenylateIBMX [28, 99] as well as the basal activities of PDE1
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Table 3. Approximate patterns of PDE isozyme in extracts from glomeruli, tubules and cultured renal cells.
cAMP-PDE cGMP-PDE
PDE1 PDE1
(cAMP) PDE2 PDE3 PDE4 (cGMP) PDE5
rat glomeruli ND 1111 11 11 11 1111
rat glomerular epithelial cells (SGE1 cells) ND ND 6 1111 ND ND
rat mesangial cells (MC) ND ND 111 1111 111 111
rat cortical tubules (suspension) 1 ND 11 111 111 111
OK cells 1 ND ND 1111 1111 1
LLCPKi cells 11 1 6 1111 1111 11
rIMCD cell 11 ND 1 111 1111 1
PDE isozyme activities were determined using the method portrayed in Fig. 5. Proportion of PDE isozyme (types) relative to total cAMP-PDE or cGMP-PDE
activity; not accounted for is “residual activity” that likely includes activity of PDE7 and PDE8 that is not influenced by known inhibitors or modulators of PDE
isozymes. cGMP-PDE activity insensitive to Ca21-calmodulin may also include PDE9. ND 5 not detected.
Fig. 6. Effect of the PDE3 inhibitor cilostam-
ide (Cs) and the PDE4 inhibitor rolipram (R),
of the combination of R 1 Cs, and of forskolin
(FSK) upon activation of protein kinase A
(PKA) (A and B), the mitogenesis assessed by
[3H]-thymidine incorporation (C) and upon
ROM generation in cultured rat mesangial
cells (D). Abbreviations are: Co, controls; R,
rolipram (10 mm); Cs, cilostamide (10 mm); R
1 Cs, 10 mm rolipram 1 10 mm cilostamide;
FSK, forskolin (10 mm). Each bar represents
the mean 6 sem of 5 to 7 observations. The
statistical significance is by the t-test. Black
bars (right) are for values of mitogenesis; stip-
pled bars (left) denote values for ROM gener-
ation. Panels A and B show in situ activation
of PKA determined by increase of (– cAMP/
1 cAMP) PKA ratio. R, Cs, R 1 Cs and
FSK all significantly activated PKA. #Values
significantly different from values with R or
Cs alone or with FSK. All stimulated values
(Cs, R, Cs 1 R or FSK) were significantly
different from controls. In panel C, the inhibi-
tion of mitogenesis determined by incorpora-
tion of [3H]-thymidine is shown. *Value sig-
nificantly different from Cs, R 1 Cs, and FSK;
the values for Cs alone, R 1 Cs and FSK are
not different from each other. Panel D shows
the inhibition of ROM generation. Values for
R, R 1 Cs, and FSK were not significantly
different from each other; 1denotes no sig-
nificant inhibitions. The content of cAMP did
not increase in mesangial cells incubated with
R or Cs alone, with R 1 Cs increased 3.5
times, and with FSK, 20 times. Data are from
[43, 95].
cyclase is not stimulated (Fig. 6) and even more when differ substantially, as can be demonstrated in studies of
MCs [15, 66]. In general, the combination of submaximalthe cyclase is stimulated by submaximal concentration
of agonist or activator [15, 66, 141]. However, the extent stimulation of adenylate cyclase by agonists with addi-
tion of selective PDE isozymes inhibitors results in aof the cAMP response in different compartments may
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pronounced increase in cAMP content, the activation of studied in a more focused way with the use of whole
kidney parenchyma as a source [59, 144]. However, incAMP PKA signaling pathways, and related functional
responses [8, 9]. Because in vivo turnover rate of cyclic the investigation of adenylate and guanylate cyclases
that are regulated by hormones, neurotransmitters andnucleotides is higher than in vitro, PDE isozyme inhibi-
tors have accentuated effects to activate the cAMP-PKA autocoids attracted much more attention than the inves-
tigation of PDEs. Consequently, studies devoted to PDEpathway in vivo [7]. Thus, when a PDE isozyme inhibi-
tor is administered in vivo, it cannot be presumed that in the kidney are relatively few. Results of studies of
PDE activities prepared from whole kidney tissue pro-its effects are quantitatively commensurate to dose–
responses determined in vitro either in cell-free or in vided initial but limited information. In view of advances
in renal pathophysiology, it became obvious that expres-whole-cell systems [7, 9]. Cells and tissues in vivo are
under the tonic influence of hormones, autocoids, and sion and functional significance of PDE isozymes ought
to be investigated in specific nephron segments, subseg-neurotransmitters that modify activities of adenylate and
guanylate cyclases. Under these circumstances, PDE in- ments, or renal cells freshly isolated or grown in culture.
Only in the late 1970s and early 1980s did the enor-hibitors will be more effective in activation of the cAMP-
PKA pathway in vivo at lower doses than predicted from mous heterogeneity of the nephron regarding the regula-
tion by hormones that act through cAMP and signalingin vitro studies [7, 9]. Other factors that can influence
the effect of PDE inhibitors in vivo include pharmacoki- become recognized [145]. The concept of a superfamily
of well-defined PDE isozymes emerged in the late 1980s,netics of the compounds, penetration into tissues and
cells, and simultaneous effects in two or more organs. and “second-generation” PDE isozyme inhibitors be-
came available at that time [7, 9–11, 23]. Therefore, onlyNevertheless, interpretation of results from studies in
vivo is less definitive than results from in vitro experi- a rather limited number of studies have focused on the
functions of PDE isozymes or isoforms in specific neph-ments and should be carefully weighed in the context of
ron segments and homogenous renal cell populations toother information.
date. This development may be illustrated by the studies
PDE isozyme inhibitors as pharmacologic agents of the cAMP-mediated signaling system in the antidiure-
tic response to [8-Arg]-vasopressin (AVP) in a murineMany PDE isozyme inhibitors are recognized pharma-
model of nephrogenic diabetes insipidus (NDI), the so-cologic agents (Table 2). In fact, some compounds were
called NDI mice [146–149]. In the first study of NDI mice,employed as drugs in medical practice long ago before
involvement of PDE was neither detected nor suspectedthey were identified as PDE inhibitors, such as theophil-
[146]. Later investigations on microdissected segments ofline, papaverine, or dipyridamole. Currently, PDE iso-
collecting ducts established that increased PDE activityzyme inhibitors, both nonspecific and PDE isozyme
plays a dominant role in the failure to elicit an increaseselective, are vigorously and intensely explored as thera-
in cAMP in response to stimulation by AVP [147], and anpeutic agents, experimentally and clinically [8, 10, 34],
even later study with the use of selective PDE inhibitorsand some PDE inhibitors are already approved for clini-
pointed to the abnormally high activity of PDE4 in col-cal use, such as the “cardiotonic” inhibitor milrinone
lecting ducts as a key pathogenic factor [106–150].in the treatment of congestive heart failure [34, 82] or
cilostazol [81] as an antithrombotic agent. Many are in
PDE isozymes as studied in nephron segmentsvarious phases of clinical and preclinical studies (Table
Information on PDEs in subdivisions of the nephron2). Currently, the most frequently available are inhibitors
is based on studies of isolated glomeruli, suspension ofof PDE3, PDE4, and PDE5. The main potential applica-
tubules, and microdissected nephron segments.tion of those PDE isozyme inhibitors, as preclinical trials
Suspensions of glomeruli and tubules. The initial studyand observations from clinical practice show, is their use
of rat glomeruli showed that activities of cGMP-PDEas antithrombotic, vasodilatory, and cardiotonic-inotro-
are higher than cAMP-PDE and that cGMP stimulatespic agents and as central nervous system antidepressants
cAMP-PDE [151]. Recent studies using selective PDEand anti-inflammatory agents (Table 2).
inhibitors indicate the presence of PDE2 in high activity,
with lower activities of PDE3 and PDE4, all of which
PDE ISOZYMES IN KIDNEY are isozymes that hydrolyze cAMP modulators (Fig. 7
AND KIDNEY EPITHELIA and Table 3) [152, 153]. In glomeruli, cGMP is hy-
The existence of enzymatic activity in the kidney that drolyzed by two isozymes; PDE5 is more abundant than
catalyzes hydrolysis of cAMP and later cGMP was noted PDE1 [152]. Localization of PDE isozymes within the
in very early studies when the cAMP system was sur- three major cell types that populate glomeruli [154] is
veyed in numerous organs and tissues that were well- not yet known or is only suspected by comparison with
known target tissues for hormone action [142, 143]. Sub- PDE isozyme profiles in glomerular cells grown in cul-
ture [66, 155]. Knowledge of PDE isozyme patterns insequently, PDE from whole kidney preparations was
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Fig. 7. Pattern of PDE isozymes in glomeruli
(C and D) and in tubules (A and B) freshly
prepared from rat renal cortex. Ordinates de-
note PDE activity fmol/min/mg protein. The
PDE isozyme activities were determined by
the method portrayed in Fig. 5. Data are from
[108].
glomeruli provides useful basic information for studies measuring cAMP-PDE and cGMP-PDE activities in mi-
crodissected segments of tubules in the studies by Jack-of pathophysiologic changes in cyclic nucleotide signal-
transduction systems. For example, increased cGMP- son, Edwards and Dousa [157]. Data on PDE activities
in microdissected tubule segments come mostly fromPDE activity and defect in cGMP accumulation that can
be corrected by the PDE5 inhibitor zaprinast was found studies done in the context of various specific topics, and
thus it is sometimes difficult to compare them with eachin glomeruli from nephrotic rats [132, 156]. Although the
type of cells containing increased cGMP-PDE remains to other [158–164]. Activities of cAMP-PDE were explored
in eight tubule segments microdissected from kidneys ofbe determined, analysis of the cGMP responses to ANP
in whole glomeruli already points to increased PDE5 three animal species frequently employed for experi-
mental studies: rat, mouse [165], and rabbit (Kusano andactivity as a pathogenic factor [132].
Phosphodiesterase isozymes in extracts of tubule sus- Dousa, unpublished data). There is a tendency toward
higher cAMP-PDE activity in cortical segments distal topensions from cortex show a substantially different pro-
file than from glomeruli (Fig. 7 and Table 3) [152]. PDE4 the loop of Henle, as compared with segments of proxi-
mal tubules [165]. Although in some segments cAMP-has the highest activity, while PDE3 and PDE1 are much
less active; all of these PDEs hydrolyze cAMP. In con- PDE activities are not different between species, distinct
differences were seen in cortical thick ascending limbtrast to glomeruli, where PDE2 is not detectable, cGMP
is hydrolyzed equally by PDE1 and PDE5 (Fig. 7). More (CTAL) and distal convoluted tubule (DCT) of mouse
and rabbit (unpublished observations). (Designation ofnephron segment-specific information was obtained from
Dousa: Cyclic-39,59-nucleotide PDE isozymes46
tubule segments are according to the international sys- ble, cyclic nucleotide signaling and PDE isozymes may
be well preserved in cultured cells. For example, a directtem [166].)
Most information about PDEs has accumulated from comparison of the cAMP signaling system in vascular
smooth muscle cells grown in primary culture from ratstudies of segments of collecting ducts; however, virtually
all were conducted without using a selective PDE inhibi- aorta and cells from freshly dissected aortic tissue re-
vealed that hormones and PDE inhibitors had in princi-tor or modulator. Results of these studies show that
cGMP-PDE activity is higher than cAMP-PDE activity ple a similar effect on fresh tissue and cells cultured from
aorta, and responses of the cAMP system differed onlyin the outer medullary collecting duct (OMCD) [148,
157], inner medullary collecting duct (IMCD) [148], and in time course and magnitude [175]. The pattern of PDE
isozymes in rat MCs grown in primary culture is pre-medullary thick ascending limb (MTAL) [159]. Activa-
tion of cAMP-PDE by Ca21 in MTAL and in OMCD served in multiple passages [66]. The pattern of PDE
isozyme activities in several types of renal cultured cells,indicates the presence of PDE1 [162], and effects of
selective PDE inhibitors indicate the presence of PDE4 determined in our laboratory, is outlined in Table 3.
Cells of tubular epithelium. LLCPK1 cells are an estab-and PDE3 in IMCD [148, 149]. There is even less infor-
mation about PDEs in proximal cortical segments [163]. lished line of renal tubular cells with AVP-sensitive ade-
nylate cyclase and have become a frequently used modelOf potential interest is a report that in a strain of mice
with hereditary X-linked hypophosphatemia (Hyp mice) for studies of cAMP signaling in renal epithelia. The
study of PDEs in wild LLC-PK1 cells revealed the pres-cAMP-PDE activity in proximal convoluted tubule
(PCT) is lower but that it is not different from controls ence of five PDE types, PDE1 to PDE5 [102]. The pres-
ence of PDE7 has not been excluded, and the evidencein proximal straight tubule (PST) or DCT [167]. In rats
fed a low-phosphate diet, cAMP-PDE, but not cGMP- for the presence of PDE3 is marginal, based solely on
minor effects of PDE3 inhibitors in cell extracts [102].PDE, is increased in cortical extracts [168]. cAMP-PDE
activity was significantly higher in the PCT but not in It appears that PDE1 and PDE4 are the isozymes that
play a role in metabolism of the cAMP pool generatedthe PST of phosphate-depleted rats [169]. Stimulation of
PKC increased cAMP-PDE, apparently PDE4, in OMCD in response to AVP [102, 176–178]. Although PDE2 is
not abundant, its functional significance is suggested bybut not in TMAL or PST of the rat nephron [170]. Obser-
vations based on indirect evidence reported by another the finding that atrial natriuretic peptide (ANP)-stimu-
lated increase in cGMP reduced increases of cAMP ingroup suggest that PKC activation may increase PDE1
activity in rabbit proximal tubular cells [171]. response to arginine vasopressin (AVP) [102].
Further insights on PDEs were obtained from studiesThe mechanism of PDE1 may be conceivably analo-
gous to the reported induction of PDE1B by PKC-a or of LLCPK1 cells stably transfected with PDE4D1A (in
the original paper [176], the enzyme was denoted as “ratPKC-e [28].
The distribution of the PDE isozyme system remains PDE3.1,” which is synonymous with the new standard
abbreviation PDE4D1A [8, 23]), a “short form” ofto be explored with current, refined methods. The avail-
ability of selective PDE isozymes, as well as the possibil- PDE4. In cloned LLCPK1-S#16 stably transfected with
PDE4DA1, PDE4 activity was fivefold to sevenfoldity of determining mRNA encoding various PDE proteins
in nephron segments by reverse transcriptase-polymerase higher than sham-transfected controls, and the increase
of cAMP in response to AVP or to forskolin was virtuallychain reaction [172, 173], by in situ hybridization [29, 51,
70], and by immunohistochemical methods [30, 71, 174] obliterated. It was restored by the addition of the PDE4
inhibitor, rolipram [176]. In control cells, inhibition ofshould make the study of PDE isozyme systems in spe-
cific nephron segments a rewarding subject of future PDE1 with the selective inhibitor 8-MeoM-IBMX en-
hanced AVP-stimulated cAMP accumulation, as did inhi-investigations.
bition of PDE4 by rolipram [176]. However, in LLCPK1-
PDE isozymes in renal cells grown in culture S#16 cells with overexpressed PDE4, only rolipram, but
not 8-Meo-IBMX, restored the stimulatory effect ofAnother source of information on the function of PDE
isozymes in renal cells comes from studies of either con- AVP. These results suggest that both PDE4 and PDE1
can be operant in the catabolism of the AVP-dependenttinuous renal cell lines or renal cells grown in primary
culture. Inherent limitations of the cell culture approach cAMP pool, but PDE1 inhibition cannot compensate for
overexpressed PDE4, a feature that points to PDE4 asin projecting results to in vivo cells are generally known.
However, the homogeneity of the cell population and the key PDE isozyme that controls AVP-dependent
cAMP metabolism in LLCPK1 cells [176–178].the possibility to conduct simple and well-defined experi-
mental maneuvers are advantages of these studies. Al- Because PDE4D1 is a “short form” of PDE4 [12] and
is inducible by cAMP [45, 50], this feature allows selectivethough the possibility that cultured cells may dedifferen-
tiate or change the phenotype in the course of in vitro experimental manipulation of PDE4 activity, but not of
other PDE isozymes. Incubation of LLCPK1-S#19 clonegrowth must be kept in mind and controlled where feasi-
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cells with only slightly overexpressed PDE4D1A, with bilized in vitro for six days [178]. The pattern of PDE
isozymes in these IMCD cells resembled that of rIMCD,agents that increase cellular cAMP [forskolin, dibutyryl
cAMP (DBcAMP), or with PDE4 inhibitors Ro-20-1724 but activity of the PDE5 isozyme was also detected [178].
PDE isozymes in glomerular cells. The pattern ofor rolipram] resulted in a significant increase in PDE4
activity. Exposure of LLCPK1-A#1 cells to increasing PDE isozymes has been determined in rat mesangial
cells grown in primary culture [66]. We found that cAMPdoses of Ro-20-1724 resulted in a gradual increment in
PDE4 activity [177, 178]. The increase in PDE4 activity is hydrolyzed by PDE4 and to a somewhat lesser degree
by PDE3 (Table 3), but other isozymes with cAMP-(maximum: D 1 60%) was inversely correlated (r 5
20.88; P , 0.05) with the decrease (maximum D 270%) PDE activity were not found. Three PDE4 isoforms were
identified in rat mesangial cells [69]. These includein AVP-dependent cAMP levels, but basal cAMP levels
remained unchanged [177, 178]. These results further RNPDE4A5, an isoform that has proline-rich SH3-bind-
ing domains [37], RNPDE4D3, which is regulated bysupport the hypothesis that PDE4 is the isozyme that is
primarily linked to the cAMP pool generated by AVP- phosphatidic acid [48] and via phosphorylation by PKA
[47], and RNPDE4D5. Isozymes PDE7 and PDE8 moststimulated adenylate cyclase. The finding is also conso-
nant with the notion that anomalously high activity of likely account for “residual” cAMP-PDE activity. Activi-
ties of the cGMP-hydrolyzing enzymes PDE1 and PDE5PDE4 can obliterate the cAMP response to AVP in NDI
mice [147–149]. The LLCPK1 cell line differs consider- are about the same [66], however, a portion of PDE5
activity is likely due to the presence of PDE9. In chro-ably from tubular epithelial cells in vivo. Nevertheless,
this model allows investigations of basic relationships matographic fractions of mesangial cell homogenates,
PDE1, PDE2, and PDE4 were found, but PDE3 andbetween AVP-dependent cAMP dynamics and PDE iso-
zymes [178]. PDE5 were not detected [181].
The glomerular epithelial cell line, “SGE1 cells” iso-Transfection of opossum kidney cells, a cell line with
many properties of proximal tubular cells, with PDE4D1A lated from rat glomeruli, retains many characteristic
properties of wild glomerular epithelial cells [182]. Weled to overexpression of PDE4 and down-regulation of
D1 dopamine receptors coupled to adenylate cyclase analyzed extracts from SGE1 cells and found high activity
of PDE4, marginal activity of PDE3 and no PDE2 or[135]. The response of the cells to dopamine was blunted,
but there was no decrease in dopamine-stimulated ade- PDE1. Surprisingly, no cGMP-hydrolyzing PDE activity
and no PDE1, PDE5, or PDE2 were detected in thesenylate cyclase activity when it was assayed in isolated
membranes from transfected cells [179]. In two trans- cells [155]. Thus, the PDE isozyme profile in SGE1 cells
substantially differs from that of mesangial cells [66].fected clones of opossum kidney cells with overexpressed
PDE4, the increase in in situ PKA activity in response Glomerular endothelial cells have not yet been investi-
gated, but by analogy from PDE isozyme profiles re-to dopamine was abolished. Because the in situ activation
of PKA is a sensitive index of cAMP-PKA pathway ported for endothelial cells from other organs [183, 184],
these cells are a likely source of high PDE2 activity foundactivation (Fig. 6) [66], these results indicate that in-
creased PDE4 activity can completely obliterate stimula- in extracts from whole glomeruli [152, 153].
tion of the cAMP-PKA pathway by the hormone [179].
Similarly, AVP not only increased cAMP in microdis-
PDE ISOZYMES IN RENAL
sected collecting ducts of NDI mice, but it also failed
PATHOPHYSIOLOGY
to increase in situ PKA activity. The addition of PDE
Pathophysiology of glomeruliisozyme inhibitors restored the PKA response [149].
In a study of IMCD cells isolated from rat kidney and Studies of isolated glomeruli in several animal models
of renal disease as well as of cultured glomerular cellsgrown in culture (rIMCD), which retain some biologic
response of wild IMCD cells, the isozymes PDE1, PDE3, point to the role of PDE isozymes in the pathobiology
of both noninflammatory and inflammatory glomerulo-and PDE4, but not PDE2 and PDE5, were detected
[180]. The PDE4 inhibitor rolipram increased accumula- pathies.
Noninflammatory glomerulopathies. Several major fluidtion of cAMP, both basal and stimulated by AVP,
whereas the AVP-dependent cAMP pool was metabo- and electrolyte disorders are characterized by the inabil-
ity of the kidney to excrete adequate amounts of salt.lized primarily by PDE1 [180]. This pattern of response
is in some points similar and in others different from the Various mechanisms accounting for renal NaCl retention
are involved, including abnormal function of glomeruliresponse of LLCPK1 cells to AVP [102, 176]. The levels
of cGMP in rIMCD cells, both basal and stimulated with with inadequate delivery of ultrafiltrate to the tubules
[132]. Glomeruli along with IMCD are major targets forANP, were enhanced by inhibitors of PDE1 [180]. To
compare properties of rIMCD cells (up to 20 passages) the action of ANP in the nephron [125]. Humphreys et
al investigated whether cGMP-mediated responses ofwith IMCD freshly isolated from kidney, PDE isozymes
were determined in IMCD cells freshly isolated and sta- glomeruli to ANP may be impaired in noninflammatory
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Fig. 8. Cyclic GMP accumulation in glomer-
uli and inner medullary collecting ducts
(IMCD), and cGMP-PDE activity in IMCD
of control rats ( ; C) and rats with nephrotic
syndrome ( ; N) due to Heymann nephritis
[140]. Each bar denotes mean 6 sem; N 5 5 to
10. The accumulation of cGMP was measured
without or with 1 mm ANP, without or with 1
mm zaprinast added into the incubation. *Val-
ues significantly lower than corresponding
controls; # cGMP-PDE activity in nephrotic
syndrome ( ); significantly higher than con-
trols ( ) by the t-test. Data are from [140]
with permission of the authors and the Journal
of the American Society of Nephrology.
experimental nephrotic syndrome induced in rats by This is contrasted with the authors’ findings in hypergly-
cemic diabetic rats, in which ANP-stimulated cGMP ac-adriamycin, a condition marked by NaCl retention [132,
133, 156]. Circulating ANP levels and ANP binding to cumulation in glomeruli is also reduced but cannot be
corrected by inhibiting PDE5; decreased density of ANPrenal receptors were not diminished, but when glomeruli
from nephrotic kidneys were incubated in vitro with ANP, receptors likely accounts for the resistance to the hor-
mone [185].the accumulation of cGMP was decreased, and the ad-
dition of the PDE5 inhibitor zaprinast restored ANP- Measurement of ANP-sensitive cGMP accumulation
in glomeruli isolated from kidneys of salt-depleted ratsdependent cGMP accumulation to the normal level [156].
Similar hyporesponsiveness of the glomerular cGMP sys- showed lower cGMP accumulation than in controls, and
this deficiency was corrected by the PDE5 inhibitor za-tem to ANP, which was corrected by zaprinast (Fig.
8), was observed in rats with nephrotic syndrome that prinast [186], an inhibitor of PDE5 and PDE9 [55, 56],
or by cicletanine, a compound believed to inhibit PDE1develops in Heymann nephritis, a model of human mem-
branous nephropathy [133]. These observations clearly [187]. The ANP-sensitive cGMP system was studied in
glomeruli from kidneys of dogs with experimental con-show that resistance of nephrotic glomeruli to ANP is a
postreceptor defect due to high cGMP-PDE activity. gestive heart failure produced by rapid ventricular pacing
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[188]. Accumulation of cGMP in glomeruli in response tent as forskolin, without measurably increasing cAMP
content. However, rolipram increased the in situ activityto ANP was greatly reduced, and the activities of PDE1
to PDE5 were increased in glomeruli [188]. The dynam- of PKA to a far lesser extent than forskolin, and the
inhibitory effect of rolipram on ROM generation wasics of cGMP were examined in glomeruli from kidneys of
rats with high-output heart failure caused by aortocaval attenuated by a PKA inhibitor [153]. Cilostamide, an
inhibitor of PDE3, had much less suppressive effect onfistula. After prolonged incubation of glomeruli with
ANP, accumulation of cGMP in glomeruli from heart- ROM generation, and inhibitors of PDE1 and PDE5
had no effect at all [153]. In general, these findings indi-failure kidneys was less than in controls, and rather para-
doxically, the glomerular cGMP-PDE activity was also cate that the cAMP-PKA signaling pathway can be acti-
vated by a decrease in PDE4 isozyme activity without alower [189]. The same authors observed that cGMP-
PDE activity is decreased in glomeruli from rats with detectable increase in cAMP content as measured by
standard radioimmunoassay, yet this subtle activation ofunilateral ureteral obstruction [190].
All these data indicate that cGMP metabolism, in par- the cAMP-PKA pathway produces a functional response
of the same magnitude as the response of “flooding” ofticular the ANP-dependent cGMP pool, is dysfunctional
in glomeruli stressed by electrolyte-fluid disturbances in cells by cAMP in response to forskolin or DBcAMP
[153]. Results show that activation of the cAMP-PKAdifferent pathophysiologic models. The initial evidence
points to increased PDE5 (and perhaps also PDE1 and pathway in glomeruli decreases ROM generation in one
or more types of glomerular cells [153].PDE9) as a major factor in blunted signaling via cGMP
[178]. Studies of cultured rat MC show that ANP-induced Mesangial cells comprise approximately 25% of the
cellular volume of glomerulus [154] and are often the focalcGMP accumulation is markedly decreased in the pres-
ence of angiotensin II, and this inhibition is abolished point of pathobiologic processes involved in immune-in-
flammatory injury that results in glomerulonephritisby IBMX and by the blocking of CaM [191]. Calcium
inophore mimics the effect of angiotensin II. These find- [198]. In various types of glomerulonephritis, growth fac-
tors and cytokines, formed both in glomerular cells andings suggest that angiotensin II, which is increased in
salt-retaining states, may activate PDE1 by increasing in infiltrating inflammatory cells, stimulate rapid prolifer-
ation of mesangial cells. The involvement of PDE iso-intracellular Ca21 and may contribute to increased hy-
drolysis of ANP-stimulated cGMP pool in situ [191]. zymes in the control of proliferation and reactive oxygen
metabolite (ROM) generation has been studied in ratAccording to recent reports, PDE3 [192] and perhaps
also PDE4 [193] may play a role in the regulation of mesangial cells grown in primary cell culture [66, 141].
It has long been known that increases in cAMP in somerenin secretion from the juxtaglomerular apparatus in
the kidney, and thus, by extension, in the pathogenesis cell types accelerates, but in other cell types inhibits, the
rate of cell proliferation [199]. First, we observed thatof pathophysiologic states associated with the anomalous
renin-angiotensin system. major increases in cAMP elicited by incubating mesan-
gial cells with forskolin or with DBcAMP were sup-Inflammatory glomerulopathies. Recent studies of non-
renal cell types and tissues have shown that some inhibi- pressed by mesangial cell proliferation [66]. Incubation
of mesangial cells with selective inhibitors of PDE iso-tors of PDE3 and PDE4 have anti-inflammatory effects
both in vivo and in vitro [73, 89, 103, 108, 136]. Several zymes, without added stimulators of adenylate cyclase,
showed that PDE3 inhibitors cause a profound decreaserecent studies have addressed the question of whether
PDE isozymes are involved in the inflammatory pro- of mitogenesis (Fig. 6) comparable to that elicited by
forskolin and DBcAMP [66]. At higher concentrationscesses in glomeruli.
The pathogenic role of ROM in renal diseases, particu- (3 mm), PDE4 inhibitors also caused a minor inhibition
of mesangial cell proliferation that was to a much lesserlarly glomerulonephritis, is now widely recognized [194],
and glomeruli are major sites of ROM generation within extent than PDE3 inhibitors [66]; at a lower concentra-
tion (1 m) PDE4 inhibitors had no antiproliferative effectthe kidney [195]. Recent studies show that PDE isozymes
are involved in the regulation of the ROM burst in neu- [15, 141]. Inhibitors of PDE1 and PDE5 were without
effect on mitogenesis. Several PDE3 inhibitors of differ-trophils [196] and macrophages [197]. In view of this,
we examined the potential modulatory effect of PDE ent chemical structure [15, 66, 141] and also the dual
PDE3/PDE4 inhibitor zardaverine [66] showed a strongisozymes on ROM generation in rat glomeruli [153] and
in cultured MCs [66]. Incubation of isolated glomeruli antiproliferative effect [66]. The efficacy of PDE isozyme
inhibitors (IC50) to decrease cAMP-PDE activity closelywith forskolin increased the cAMP content many-fold,
and increased at maximum the in situ activity of PKA correlated with their potency for inhibition (IC50) of mi-
togenesis [141]. PDE3 inhibitors suppressed mesangialand suppressed ROM generation [153]. When glomeruli
were incubated with PDE isozyme inhibitors, without cell mitogenesis not only in the ambient state, that is,
when under the autocrine/paracrine influence of endoge-stimulation of adenylate cyclase, the PDE4 inhibitor roli-
pram suppressed ROM generation to a comparable ex- nous growth factors and cytokines generated by mesan-
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gial cells, but also when stimulated by maximum doses whereas PDE3 inhibitors cilostamide and lixazinone had
no effect [15, 141]. The IC50 value for cAMP-PDE inhibi-of added growth factors, such as epidermal growth factor
and platelet-derived growth factor [66]. Inhibition of tion corresponded to the IC50 for suppression of ROM
generation. The maximum inhibition of ROM genera-PDE3 suppressed mitogenesis to a comparable degree
as forskolin, but without a detectable increase in cAMP tion by rolipram was of a similar magnitude as inhibition
by forskolin or DBcAMP [141], in spite of the fact that(Fig. 6); however, the in situ activity of PKA measured
by the (2 cAMP/1 cAMP) PKA activity ratio was in- rolipram activated in situ PKA far less than forskolin
(Fig. 9). These results also suggest that a minor inhibitorycreased, and H89, a specific inhibitor of PKA, reversed
the effect of the PDE3 inhibitor cilostamide on mesan- effect of cilostamide on ROM generation in whole glo-
meruli was likely because of its action in cell types othergial cell proliferation [66].
The question was whether and how the increase in than mesangial cells [153]. The mechanism by which
selective activation of the PDE4-linked cAMP-PKA sys-the PDE3-linked cAMP pool in mesangial cells might
have interfered with signaling pathways that increase tem in mesangial cells inhibits ROM generation is not yet
known. The major site of ROM generation is NADPHthe rate of mesangial cell proliferation. In response to
incubation of mesangial cells with PDE isozyme inhibi- oxidase, a multicomponent enzyme within the plasma
membrane that consists of seven subunits that are assem-tors, the activity of extracellular signal-regulated protein
kinase (ERK), a key enzyme in one of the currently bled in an active state [62, 117]. We hypothesize that
PKA, by phosphorylating Rap 1a, one of the subunits,known family of MAPK phosphorylation pathways [200,
201], was suppressed in both the ambient state and when prevents assembly and activation of NADPH oxidase in
plasma membranes of mesangial cells (Fig. 10). How-stimulated by epidermal growth factor [66]. Our working
hypothesis is that PKA activated by an increase in the ever, an alternative mechanism(s) by which cAMP inhib-
its ROM generation in mesangial cells is not excluded.cAMP pool linked to PDE3 phosphorylates c-raf-1 pro-
tein kinase on Ser43 [203] and perhaps also on Ser621 Rolipram and denbufylline are inhibitors that do not
distinguish between isoforms and splice variants of the[204], and thereby inhibits its activity on the whole ERK
signaling pathway, which ultimately results in a de- PDE4 family. Conceivably, a PDE4 isoform such as ro-
dent RNPDE4A5 or human homologue HSPDE4A4B,creased rate of mitogenesis (Fig. 9). Such negative cross-
talk between the PKA and ERK signaling pathways has which have an N-terminal region with an SH3-binding
domain [37, 38], may associate with subunits of NADPHbeen shown in nonrenal cell types [205]. MAPK phos-
phorylation cascades, including ERK, are “progressively oxidase, which possess multiple SH3 domains [62, 117]
in mesangial cells as it does in other cell types. If this isultrasensitive” systems in which the initial signal can be
highly amplified [206]. Therefore, inhibition of c-raf-1 the case, only a fraction of all PDE4 isozymes that are
present in mesangial cells may be functionally linked toprotein kinase, the first step in the ERK cascade, may
have a profoundly suppressive effect on ERK activation modulation of ROM generation [15]. Recent results
show that RNPDE4A5 is, indeed, expressed in rat mes-and mitogenesis (Fig. 9). It cannot be excluded that
PDE3-linked activated PKA might conceivably block angial cells [69].
Actions of PDE isozyme inhibitors on ROM genera-mitogenic signaling systems at one or more other points,
and the exact mechanism remains to be elucidated. An- tion and mitogenesis in cultured mesangial cells indicate
that PDE3 and PDE4 isozymes may function in mesan-other mechanism by which cyclic nucleotide signal trans-
duction pathways may decrease ERK activity involves gial cells to compartmentalize cAMP-PKA signal trans-
duction pathways for separate regulation of two distinctcGMP (Fig. 9). ANP, an agonist of guanylate cyclase,
inhibits mitogenesis in mesangial cells [197]. Incubation functional responses, both within one single mesangial
cell (Fig. 11). This notion is in accord with the observa-of mesangial cells with ANP decreased MAPK activation
in response to endothelin and to phorbol 12,13-dibuty- tion that increases in in situ PKA activity after incubation
of mesangial cells with the PDE4 inhibitor rolipram andlate, an activator of PKC [207]. Another study of cultured
rat mesangial cells has shown that cGMP increased in the PDE3 inhibitor cilostamide are additive (Fig. 6),
and the inhibitors selectively block ROM generation andresponse to ANP or nitric oxide results in activation of
mitogen kinase phosphatase that dephosphorylates and mitogenesis [15, 66, 141]. The activities of PDE3 and
PDE4 in cell-free extracts from mesangial cells are com-thus decreases the activity of ERK [202]. I have observed
that this antimitogenic effect can be accentuated by in- parable [66]. However, when intact mesangial cells are
incubated in the presence of forskolin, the maximumhibitors of PDE1 and PDE5 (unpublished observations).
Because a PDE4 inhibitor decreased ROM generation inhibitory doses of PDE4 inhibitors caused more than
200-fold increase in cAMP content, whereas in contrast,in whole glomeruli [153], we investigated whether the
PDE4-linked cAMP pool can cause suppression of ROM maximum inhibitory doses of PDE3 inhibitors barely
doubled cAMP levels [66, 141]. Apparently, in intactgeneration in mesangial cells. The PDE4 inhibitors roli-
pram and denbufylline blocked ROM generation in them, mesangial cells, as yet unknown factors cause the cAMP
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Fig. 9. PDE isozymes in regulation of mito-
genesis in mesangial cells (MC). Schematic
depiction of negative crosstalk between extra-
cellular receptor kinase (ERK) pathway (also
referred to as mitogen-activated protein ki-
nase pathway, MAPK) and cAMP-PKA path-
way linked to PDE3 in MC. Growth factors
bind to their respective receptors and, via
adaptive proteins Shc, Grb, and GTP/GDP
exchange factor Sos, activate Ras attached to
the plasma membrane. Once Ras is activated,
it proceeds to interact with and stimulates Raf-
1 protein kinase. In ERK pathway Raf-1 pro-
tein kinase phosphorylates and activates mito-
gen extracellular kinase (MEK), which in turn
phosphorylates and activates ERK kinase that
translocates to nucleus and, directly or indi-
rectly, activates nuclear transcription factors.
Selective inhibition of PDE3 increases cAMP
and activates PKA and activated PKA, phos-
phorylates and thereby inhibits Raf-1 protein
kinase activity. A decrease in Raf-1 activity
consequently results in decreased activity and
subsequent phosphorylation steps in the path-
way (MEK and ERK protein kinases) and
ultimately in decreased phosphorylation of
nuclear transcription factors and decreased
the rate of DNA synthesis. ERK protein ki-
nase can be also dephosphorylated and inacti-
vated by dual-specificity mitogen kinase phos-
phatase (MKP), an enzyme that may be
induced by increased cGMP in response to
atrial natriuretic peptide (ANP) [162]. In MC
the cAMP is hydrolyzed by several of PDE
isozymes; when PDE3 activity is decreased,
cAMP accumulates in a specific pool and acti-
vates PKA that, in turn, inhibits raf-1 protein
kinase and the whole ERK cascade. Adenyl-
ate cyclase (AC) that catalyzes cAMP synthe-
sis is regulated by hormones and autocoids
that act on receptors (REC) coupled to AC
by tetrameric G-proteins (G). Possibly, PKA
may act on some other steps in the mitogenic
signal transduction pathways, however, there
is little evidence for such action. Details are
in the text.
pool metabolized by PDE4 to be far larger than the pool mesangial cell population are similar to those found in
human glomerular diseases involving the mesangium,metabolized by PDE3. This finding is consistent with
the existence of putative PDE isozyme-linked cAMP namely IgA nephropathy [198]. Rats with antithymic
serum-induced MPGN received the PDE3 inhibitor lixa-compartments in mesangial cells (Fig. 11). Conceivably,
various specific isoforms of PDE4 detected in these cells zinone and the PDE4 inhibitor rolipram continually via
osmotic minipumps [117]. Administration of PDE iso-[69] may have additional roles in functional compartmen-
talization of cAMP-PKA signaling pathways [15]. zyme inhibitors prevented the development of protein-
uria, a major functional change in the acute phase ofStudies on models of glomerulonephritis. Observa-
tions in vivo led us to explore whether PDE isozyme MPGN [117]. Histologic and immunohistologic examina-
tion of the kidneys showed marked suppression of patho-inhibitors can also suppress pathobiologic processes in
glomeruli in vivo. The study was conducted on the exper- logic changes in glomeruli of MPGN rats treated with
the PDE isozyme inhibitors (Fig. 12). Analysis usingimental model of mesangial proliferative glomerulone-
phritis (MPGN) induced in rats by injection of antithymic immunohistochemical methods showed a reduced num-
ber of proliferating cells (Fig. 12), less infiltration byserum containing anti-Thy-1.1-antibodies [117]. This ani-
mal model MPGN is characterized by a phase of rapid macrophages, and decreased myofibroblastic transfor-
mation, assessed by expression of smooth muscle a-actinproliferation and phenotypic transformation of mesan-
gial cells. In many ways, the pathologic changes in the [117]. In subsequent and still continuing studies, we have
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Fig. 10. Proposed mechanism by which the
cAMP pool linked to PDE4 inhibits activation
of NADPH oxidase in plasma membranes of
mesangial cells (MC). NADPH oxidase con-
sists of four cytoplasmic subunits p47phox,
p67phox, p40phox and the GTP-binding protein
rac, and three subunits within the membrane
including gp91phox, p22phox and Rap-1a, another
GTP-binding protein. In response to stimuli,
some of which involve phosphorylation of
p47phox by PKC, cytoplasmic and membrane
subunits assemble into an active NADPH oxi-
dase complex that catalyzes the generation
of oxygen superoxide anion from molecular
oxygen. Phosphorylation of Rap-1a subunit by
PKA inhibits its interaction with other sub-
units and consequently the assembly of
NADPH oxidase into an active complex [33].
Inhibition of PDE4 activity, but not other
PDE isozymes, results in the accumulation of
cAMP in a specific pool linked to PDE4 and
activates PKA that, in turn, phosphorylates
Rap-1a and impedes the NADPH oxidase as-
sembly and activation.
Fig. 11. Schematic depiction of proposed
compartmentalization of cAMP-PKA signal-
ing pathway by PDE isozymes in mesangial
cell (MC). The intracellular cAMP pool hy-
drolyzed by PDE3 regulates mitogenesis in
MC [43]. Inhibition of PDE3 by selective in-
hibitors (cilostamide, lixazinone) causes an in-
crease in this PDE3-specific cAMP pool and
activates adjacent PKA. The protein kinase
A (PKA) phosphorylates c-raf-1 and thereby
inhibits the mitogen-stimulated ERK phos-
phorylation cascade at the initial point (see
Fig. 6), which leads to suppression of mitotic
synthesis of DNA. On the other hand, cAMP
hydrolyzed specifically by PDE4 regulates re-
active oxygen metabolite (ROM) generation
in MC [95]. Inhibition of PDE4 by selective
inhibitors (rolipram, denbufylline) leads to an
increase of another distinct cAMP pool and
activates adjacent PKA. PKA, probably via
phosphorylating Rap-1a, then decreases the
NADPH oxidase assembly and ROM genera-
tion (see Fig. 7). It is not yet determined
whether PKAs adjacent to PDE3 and PDE4
are two distinct isozymes, PKA-I and PKA-
II, respectively, or isoforms of the same PKA
isozyme that are localized by anchoring to
specific intracellular structures.
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state, the effects of PDE inhibitors are greatly accentu-
ated [7, 9]. Along with many other hormones and auto-
coids that act on glomeruli [210], the recently discovered
peptide adrenomedullin, which is synthesized in mesan-
gial cells, is a potent stimulator of cAMP synthesis in
mesangial cells [211]. As a recent study shows, activation
of the cAMP-PKA pathway by adrenomedullin in mes-
angial cells and in the macrophage cell line inhibits both
mitogenesis and ROM generation [212].
With respect to other types of glomerulonephritis, of
major interest is a recent preliminary report that admin-
istration of the PDE4 inhibitor rolipram may have a
beneficial effect on nephrotoxic glomerulonephritis in
rats [118]. The authors found that the administration of
rolipram had both a preventive and a therapeutic effect
in terms of abated albuminuria, less histopathologicFig. 12. Effect of PDE inhibitors upon mesangial cell (MC) prolifera-
changes in glomeruli, and also a decrease in the urinarytion in glomeruli of rats with experimental mesangial proliferative glo-
merulonephritis (MPGN) induced by single injection of ATS (anti- excretion of tumor necrosis factor-a (TNF-a). A full
Thy-1.1 nephritis). The content of proliferating cell nuclear antigen report of this study will be of major interest. Rolipram
(PCNA) in glomeruli was determined immunohistochemically by count-
and other PDE4 inhibitors were shown to selectivelying of positively stained cells per glomerulus (each value is based on
analysis of 50 glomeruli). The control rats without MPGN or treat- suppress de novo synthesis, and to release TNF-a and
ment(h), rats with MPGN( ) and MSGN rats treated with a combina- other proinflammatory cytokines in macrophages and
tion of lixazinone and rolipram ( ) are compared; each group consists
other inflammatory and immunocompetent cells [90,of mean 1 sem of N 5 3 to 5 rats. P values for significance of differences
are by the t-test. Data are from [157]. 213–217]. Administration of PDE4 inhibitors in vivo sup-
pressed or prevented experimental arthritis [216, 217]
and several other types of inflammatory lesions [217]. In
these in vivo models, PDE4 inhibitors decreased de novo
found that administration of the same dose of the PDE3 synthesis and tissue accumulation of the proinflamma-
inhibitor lixazinone alone blocked mesangial cell prolif- tory cytokines TNF-a, interleukin-b, and interferon-g
eration to a similar degree as in the first study [15, 208], (INF-g) [213–217]. The therapeutic effect of PDE4 inhib-
whereas the PDE4 inhibitor rolipram alone did not show itors in an animal model of experimental autoimmune
significant suppression of pathologic changes in MSGN encephalomyelitis, a disease that resembles multiple
[208]. Higher doses of rolipram than those used in the sclerosis, was also attributed to decreased TNF-a genera-
subsequent study [117, 208] given subcutaneously de- tion [124, 125].
creased mesangial cell proliferation and reduced protein- Taken together, these observations suggest that PDE
uria, albeit to a lesser extent than with lixazinone (T.P. isozymes in renal cells and/or inflammatory cells that
Dousa and J.P. Grande, preliminary observations). Thus, infiltrate renal tissue could be targets for PDE isozyme
administration of PDE isozyme-selective inhibitors in inhibitors aimed at suppressing various pathobiological
vivo suppressed pathobiologic processes in mesangial processes in glomeruli by interfering with signal trans-
cells in vivo, as might have been expected based on the duction mechanisms. Various PDE inhibitors, alone or
studies of cultured mesangial cells in vitro [66]. According in a combination, can be selectively targeted to suppress
to a recent study, glomerular ERK activity is dramati- different types of immune-inflammatory injury and rep-
cally increased in experimental proliferative glomerulo- resent a novel “signal transduction pharmacotherapy”
nephritis in rats [209]. Results also suggest that in MSGP [21] of glomerulonephritis.
and similar types of glomerulonephritis, the inhibition
PDE isozymes in tubular disordersof PDE3 may be a basis for a novel mode of pharmaco-
therapy [117]. It should be stressed, however, that these Studies of several models of experimental diseases
initial studies were conducted with the use of a single suggest involvement of PDE isozymes in the pathophysi-
dose of inhibitors, and different doses, or a different ology of renal tubular dysfunction.
ratio of doses of PDE3 and PDE4 inhibitors, might have Mice with hereditary nephrogenic diabetes insipidus
a qualitatively or quantitatively different effect. Further- (NDI). As mentioned previously, hereditary NDI in mice
more, lower doses of PDE inhibitors might be sufficient was identified as the first hereditary renal disease be-
to produce a therapeutic effect [7, 9, 15]. As in all other cause of abnormal activity of PDE isozymes [147, 148].
cell types, adenylate cyclase in MCs in vivo is under Briefly, these in vitro studies indicate that increased ac-
tivity of cAMP-PDE, namely PDE4, in IMCD accountsthe influence of many stimulators, and in this functional
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ology of any variants of human NDI syndromes. The
genetic defects in NDI documented thus far are at the
AVP receptor or post-cAMP components of the signal-
ing pathway [219]. Nevertheless, the NDI-mouse model
serves as a paradigm of a renal disease with hereditary
unresponsiveness to a hormone that is, by all present
evidence, caused by increased activity of a PDE isozyme.
In microdissected IMCD from adrenalectomized rats
with a urinary concentrating defect, cAMP-PDE activity
was increased and AVP-stimulated cAMP accumulation
was decreased, whereas adenylate cyclase activity was
not changed [164]. All biochemical and functional abnor-
malities were corrected by administration of dexametha-
sone. The findings point to the importance of cAMP-PDE
in AVP action and suggest that increased cAMP-PDE
may be a pathogenic factor also in acquired forms of
vasopressin resistance [164].
Increased activity of cGMP-PDE in collecting ducts
in nephrotic syndrome. Atrial natriuretic peptide is a
potent regulator of Na1 transport in IMCD. The mecha-
nism of ANP action in IMCD cells involves a stimulation
of guanylate cyclase and an increase in cGMP that inhib-
its the Na1 channel in luminal membrane of IMCD cells.
Seminal observations by Humphreys et al point to a role
of cGMP-PDE in the blunted ability of ANP to enhance
Fig. 13. Activity of cAMP-PDE (A) and arginine vasopressin (AVP)- Na excretion in IMCD from rats with nephrotic syn-
dependent cAMP accumulation (B) in inner medullary collecting ducts drome of different origins [132, 133, 156]. In rats with
microdissected from the kidneys of normal mice (controls) and mice
nephrotic syndrome produced either by adriamycin [156]with hereditary nephrogenic diabetes insipidus (NDI-mice). The sam-
ples were incubated without (controls, ) or with either 0.1 mm roli- or by immune-complex Heymann nephritis [133], levels
pram, a PDE4 inhibitor ( ), or with 0.1 mm cilostamide, a PDE3 of circulating ANP and its binding to receptors in IMCD
inhibitor ( ). In A, *significantly different from all other values, # values
cells were not diminished, but incubation of collectingsignificantly lower than that without inhibitors. In B, * significantly
different from controls and R, # not significantly different from controls. duct segments with ANP in vivo resulted in low accumu-
Whereas both R and Cs inhibited cAMP-PDE activity, only R restored lation of cGMP (Fig. 8). The activity of cGMP-PDE
cAMP accumulation in IMCD of NDI mice.
measured in homogenates of IMCD segments was in-
creased [156, 133]. Urinary excretion of cGMP in re-
sponse to acute volume expansion in vivo was also de-
creased [132, 133, 156]. The selective inhibitor of PDE5for the failure of AVP to increase cAMP [148] and to
activate in situ PKA [149], and to elicit an antidiuretic zaprinast (which may also inhibit PDE9) restored cGMP
accumulation in response to ANP in IMCDs incubatedeffect [218]. Both the PDE4 inhibitor rolipram and the
PDE3 inhibitor cilostamide decrease cAMP-PDE activ- in vitro and, given in vivo restored the ability to increase
salt and cGMP excretion in response to a volume loadity in IMCD microdissected from NDI mice, but only
the PDE4 inhibitor rolipram restores AVP-stimulated [132, 133, 156]. Thus, increased PDE5 activity (and per-
haps also PDE9 activity) in cells of collecting ducts incAMP accumulation (Fig. 13). Although in the initial
studies in vivo rolipram was administered together with nephrotic syndrome of different etiologies may account
for hyporesponsiveness to ANP and blunted natriuresis.cilostamide, later experiments indicate that the PDE4
inhibitor alone can restore the functional response in The finding suggests that decreased responsiveness to
ANP both in glomeruli and tubules (Fig. 8) is due tovitro and in vivo [218]. The increased PDE activity is
due to a higher Vmax [150], a finding compatible with enhanced cGMP catabolism. Furthermore, the investiga-
tors have shown that in the abnormal sodium metabolismthe possibility that PDE4 is overexpressed in IMCD as
similarly demonstrated in studies of LLCPK1 cells [105, resulting from hepatic injury due to ligation of the com-
mon bile duct in rats [220], a condition that does not176–178]. It will be important to determine which sub-
type and isoform of PDE4 is overexpressed or whether involve primary renal disease, the blunted response of
the IMCD to ANP can be corrected, at least in part, bya mutant enzyme accounts for high PDE4 activity in
collecting ducts of NDI mice. The pathogenesis of mu- administration of the PDE5 inhibitor zaprinast in vivo
and in vitro [220]. Unlike the case of NDI mice, increasedrine NDI syndrome may be unrelated to the pathophysi-
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activity of PDE5 in these salt-retaining states is not likely ure, the administration of Ro-20-1724 attenuated renal
hereditary and may be caused by extrarenal factors. Fu- vasoconstriction, reduced the decline of renal blood flow
ture studies should show if increased activity of PDE5 is and glomerular filtration rate, and improved overall sur-
due to overexpression of PDE5 or whether an abnormal vival rate [223]. The mechanisms accounting for the ben-
PDE5 isoform is induced in the nephrotic state, and by eficial effect of this PDE4 inhibitor on endotoxemic acute
which mechanism. Because it is now known that zaprinast renal failure are yet to be determined. Endotoxin is known
also inhibits PDE5 besides PDE9 [55, 56], another iso- to stimulate synthesis and release of proinflammatory
zyme selective for cGMP that is highly expressed in the cytokines such as TNF-a, interleukin-1b, or INF-g, and
kidney [55], the possible role of PDE9 should be investi- blockade of synthesis and release of cytokines [213–217]
gated as well. The role of other cGMP-hydrolyzing PDE either in tubular epithelial cells [224] or in peritubular
isozymes, namely that of PDE1, activated in situ also cells by PDE4 inhibitors might have been the basis of the
should be clarified. Needless to say, nephrotic syndrome observed beneficial effect. Relaxation of vascular smooth
and other states of sodium retention are another area muscle [225] and enhancement of kidney perfusion by
ready for development of “signal transduction pharma- the PDE4 inhibitor may be another beneficial factor.
cotherapy” targeted to PDE5 and other cGMP-hydrolyz- These stimulating findings await in-depth analysis of the
ing isozymes. mechanism.
PDE isozymes and acute renal failure. The possible In ischemic acute renal failure, according to a recent
role of PDE isozymes in the pathogenesis or treatment report, administration of the PDE5 inhibitor zaprinast
of acute renal failure has recently been approached with greatly accelerated recovery from established ischemic
the use of selective PDE inhibitors. acute renal failure caused by clamping the renal arteries
Injection of folic acid causes acute renal failure, which in rats [226]. Infusion of zaprinast dramatically improved
is characterized by exceedingly rapid proliferation of postischemic glomerular filtration rate and increased cor-
tubular cells without detectable changes in glomeruli tical and outer medullary blood flow. In contrast to ef-
[221]. We examined whether accelerated proliferation fects of the PDE5 inhibitor, treatment with ANP, a po-
of tubular epithelial cells may be modulated by changes
tent stimulator of cGMP synthesis in glomeruli and
in activity of PDE isozymes [152]. Administration of
collecting ducts [173], had no effect. The therapeuticthe PDE3 isozyme inhibitors cilostamide or cilostazol,
effect of the PDE5 inhibitor was attributed primarily totogether with the PDE4 inhibitor rolipram or the potent
a favorable action on the renal circulation, especially ininhibitor of PDE3 lixazinone alone, almost completely
the medulla, and such an interpretation is in accord withblocked the burst of tubular cell proliferation in response
the presence of PDE5 in vascular smooth muscle cellsto folic acid, whereas rolipram by itself had no effect
of nonrenal origin and its role in vasorelaxation [227].[152]. The antimitogenic effect of the PDE inhibitors
One feature with respect to the action PDE isozymewas comparable in extent to the effect of the potent
inhibitors in vitro and in vivo should be kept in mindDNA transcription inhibitor actinomycin-D [152, 221].
when considering their use as pharmacotherapeutics. AsCortical tubules contain significant PDE3 activity, al-
shown in several examples here, the decrease of cAMPthough the exact localization is not yet determined. Con-
or cGMP hydrolysis by specific PDE isozymes has aceivably, the mechanism by which PDE inhibitors block
prolonged and sustained enhancing effect on signalingmitogenesis is similar to that proposed to occur in rapidly
pathways, even in situations when large doses of agonistsproliferating MC in vitro and in vivo [15, 66, 117], that
that stimulate cAMP or cGMP synthesis are withoutis, via negative cross-talk between PDE3-cAMP-PKA
effect [132, 149, 226]. It is reasonable to expect that theand ERK signaling pathways (Fig. 9). It is plausible that
effect of PDE inhibitors on PDE isozymes will not be,only those renal cells, tubular or glomerular, that prolif-
in most instances, subject to desensitization as is theerate at an accelerated rate are susceptible to the inhibi-
case after prolonged stimulation of receptors coupled totory effect of the PDE3-linked cAMP pool. This would
adenylate cyclase with high doses of the hormone.be an advantage for the design of targeted pharmaco-
therapy with PDE isozyme inhibitors.
Acute renal failure that develops in the course of endo-
CONCLUSIONS AND PERSPECTIVEStoxic shock has a prominent vascular component. In stud-
Current information pertaining to the system of PDEies of rats with acute renal failure induced by infusion
isozymes in kidney and renal cells, although still limitedof E. coli lipopolysaccharide the administration of the
and fragmentary, shows that this key component of cyclicPDE4 inhibitor Ro-20-1724 prior to injection of endo-
nucleotide signaling pathways is crucial to understandtoxin prevented the decrease of renal blood flow, low-
the pathobiology of renal diseases and the design ofered renal vascular resistance, and also prevented the
novel “signal transduction” pharmacotherapeutic inter-decline of glomerular filtration rate [222]. In rats with
already developed endotoxin-induced acute renal fail- ventions. There are major areas in the spectrum of renal
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diseases, yet untouched, in which the study of PDE iso- and/or cGMP synthesis. These findings from studies of
nonrenal tissues constitute a compelling rationale for thezymes should be a high priority.
Multiple studies have accrued evidence that abnormal study of PDE isozymes and the effects of their selective
inhibitors in various facets of renal transplantation.cAMP metabolism plays a significant role in the patho-
genesis of polycystic kidney diseases [228]. As implied In conclusion, this evidence clearly shows that PDE
isozymes are involved in the modulation of biological andin a recent editorial comment [229], it is reasonable to
consider that cAMP’s effect on fluid secretion or cell pathobiological processes in renal cells, and demonstrate
that PDE-specific inhibitors may favorably influence theproliferation in the course of cystogenesis may be regu-
lated by cAMP pathways that are related to specific PDE skein of pathophysiological entities from glomerulone-
phritis through an impaired renal handling of sodium inisozymes, and this may clarify some apparently paradoxi-
cal findings pertaining to the role of cAMP. Likewise, the nephrotic syndrome, to various forms of acute renal
failure. Well-designed and focused studies of PDE iso-elucidation of the PDE isozyme superfamily’s role in the
development of polycystic kidney disease may provide zymes and the effects of selective PDE inhibitors in renal
cells and kidney tissue are bound to elucidate the regula-a rational basis for novel therapeutic avenues for the use
of selective PDE inhibitors. tion of renal function by cyclic nucleotide signaling that
have eluded detection thus far, and point to novel targetsAnother major area in which PDE isozymes may play
an important role is in the theory and practice of renal for “signal transduction” pharmacotherapies [21].
transplantation. Drawing on analogies from studies of
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APPENDIX231] may be fundamental mechanisms that account for
vascular dysfunction and increased capillary permeabil- Abbreviations used in this article are: ANP, atrial natriuretic pep-
tide; AVP, [8-Arg]-vasopressin; CaM, calmodulin; cAMP, cyclic-39,59-ity and decrease in survival of grafts. Inhibitors of PDE3
adenosine monophosphate; cCMP, cyclic-39,59-cytidine phosphate;
and PDE4 or dual PDE3/PDE4 inhibitors blocked the cGMP, cyclic-39,59-GMP; DBcAMP, dibutyryl cAMP; EHNA, erythro-
9-(2-hydroxyl-3-nonyl)-adenine; ERK, extracellular signal-regulatedincrease in endothelial permeability in vitro [126], and
protein kinase; FSH, follicle stimulating hormone; HARBS, high affinityapplication of PDE3 and PDE4 inhibitors in vivo that
rolipram-binding sites; IBMX, 3-isobutyl-1-methyl-xanthine; IMCD, in-
diminish or prevent a drop in cAMP content improve ner medullary collecting ducts; MAPK, mitogen-activated protein ki-
nase; MC, mesangial cells; 8-MeoM-IBMX, 8-methoxymethyl-IBMX;vascular homeostasis and enhance organ preservation
MSGN, mesangial proliferative nephritis; NDI, nephrogenic diabetes[127, 128]. Inhibition of the cGMP breakdown via PDE5
insipidus; PDE, phosphodiesterase; PKA, protein kinase A; PKC, pro-
by the selective PDE5 inhibitor zaprinast significantly tein kinase C; PKG, protein kinase G; rIMCD, rat IMCD; ROM,
reactive oxygen metabolites; SH2, Src homology 2; SH3, Src homology 3;improved the preservation of heart and lung tissues in the
TNF-a, tumor necrosis factor-a.course of and immediately after transplantation [135].
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